2013
Annual scientific report Institut d’Investigació Biomèdica de Girona Dr. Josep Trueta
2
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
3
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
INDEX
6
14
28
INTRODUCTION PRESENTATIONS IDIBGI ORGANIZATION
FACTS AND FIGURES JOURNALS
NEWS
32
42
56
CARDIOVASCULAR AREA CARDIOVASCULAR GENETICS GIRONA HEART REGISTRY (REGICOR)
METABOLISM AREA BRONCHIECTASIS NUTRITION, EUMETABOLISM AND HEALTH PEDIATRIC ENDOCRINOLOGY
NEUROSCIENCE AREA AGING, DISABILITY AND HEALTH CEREBROVASCULAR PATHOLOGY MEDICAL IMAGING NEURODEGENERATION AND NEUROINFLAMMATION
74
90
98
ONCOLOGY AND HEMATOLOGY AREA HEPATOBILIARY & PANCREATIC SURGERY AND ONCOLOGY DESCRIPTIVE EPIDEMIOLOGY, GENETICS AND CANCER PREVENTION HEMATOLOGY MOLECULAR ONCOLOGY
GROUPS ASSOCIATED WITH THE IDIBGI
GROUPS ASSOCIATED WITH THE IDIBGI
ICS INTERNAL MEDICINE MICROBIOLOGY AND INFECTIONS IN THE CRITICAL PACIENT NEPHROLOGY
UNIVERSITY OF GIRONA BIOCHEMISTRY OF CANCER BIOPHARMACEUTICAL RESEARCH COMPUTER VISION AND ROBOTICS CONTROL ENGINEERING AND INTELLIGENT SYSTEMS HEALTH AND HEALTHCARE HEALTH PSYCHOLOGY PROTEIN ENGINEERING STATISTICS AND DATA ANALYSIS STATISTICS, ECONOMETRICS AND HEALTH
INTRODUCTION
PRESENTATION Albert Barbera, PhD Director - CEO Another year has gone by and it is a great pleasure for me to present the Annual Report of the IDIBGI for 2013. I invite you to take a look through it and reflect on the outstanding scientific work being done by the IDIBGI research groups. Similarly to last year’s report, an overall view of the institution as a whole is given at the outset and then we take a look at each of the research groups associated with the IDIBGI in turn. These are complicated times with large cuts in research funding making being a researcher almost a Herculean task. Therefore, first of all I want to acknowledge the dedication and effort put in by all the IDIBGI researchers day in, day out. Thanks to them the IDBIGI is managing to maintain its scientific quality and impact. It is a real pleasure to be leading such a stimulating project. It is important to highlight some of this year’s main achievements. During 2013, the Catalan Government has accredited IDIBGI’s Biobank, which, furthermore, has received the backing of the Instituto de Salud Carlos III to renew its participation in the Spanish network of biobanks. These important steps help to consolidate our Biobank as an invaluable support to biomedical research. Another important accomplishment was the holding of the first meeting of the IDIBGI Scientific Advisory Board, formed by outstanding members of the scientific community. Finally, during 2013 IDIBGI was evaluated by the CERCA Institution of the Generalitat de Catalunya. This evaluation, together with the recommendations of the Scientific Advisory Board, will pave the way for the IDIBGI’s future strategic actions. Both the Scientific Advisory Board and the CERCA evaluation pointed out that despite the IDIBGI’s young age and small size the results accomplished so far have been impressive and they both highlighted the great potential that IDIBGI has for the future. The way forward for the IDIBGI is to continue to strive for excellence in scientific production, to potentiate the valorisation and transfer of all the knowledge generated, and to improve the dissemination and outreach activities of the institute. If we work together for these three important objectives our full potential will be realised: we will make our mark on the research community, not only nationally but also internationally, and we will meet our obligations to society, ensuring that our research, our collective knowledge, has a beneficial impact on the health of our citizens.
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
INTRODUCTION
IDIBGI ORGANIZATION
BOARD OF TRUSTEES
EXECUTIVE BOARD
CEIC
SCIENTIFIC ADVISORY BOARD
CEEA DIRECTOR
INTERNAL SCIENTIFIC COMMITTEE
RESEARCH GROUPS
SCIENTIFIC PLATFORMS
ADMINISTRATIVE MANAGEMENT
BIOBANK
CLINICAL RESEARCH UNIT
ACCOUNTING AND FINANCE AREA
STATISTICAL & METHODOLOGICAL ASSESSMENT
SCIENTIFIC COORDINATION AREA
INTRODUCTION
Board of Trustees President 1st Vice-President 2nd Vice-President Members
Secretary
Boi Ruíz García Minister for Health – Catalan Government
Andreu Mas-Colell Minister for Economy and Knowledge – Catalan Government
Anna Mª Geli de Ciurana Dean of the University of Girona
Carles Constante Beitia Director General of Health Planning and Resources Josep Trias i Figueras Regional Delegate Gabriel Capellà Munar Responsible for Health Research and Innovation Antoni Castellà i Clavé Secretary for Universities Iolanda Font de Rubinat Director General of Research Lluís Rovira Pato Director of CERCA– Catalan Government Josep Maria Martorell Rodon Director General of Research, Catalan Government Josep Maria Gómez Pallarès Manager of the University of Girona Josep Calbó Angrill Vice-Dean for Research at the University of Girona Martí Casadesús Fa Vice-Dean for Educational Quality at the University of Girona Joan Profitós Tuset President IAS (Healthcare Institute) Girona Josep Maria Vilà Cortasa ICO Managing Director Antoni Juan Pastor Hospital Director at the Dr. Josep Trueta University Hospital of Girona Vicenç Martínez Ibáñez Catalan Health Institute (ICS) Regional Manager for Girona
Albert Barberà Lluís Director of the IDIBGI
10
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
INTRODUCTION
Executive Board President Members
Secretary
Gabriel Capellà Munar Responsible for Health Research and Innovation
Josep Maria Martorell Rodon Director General of Research, Catalan Government Lluís Rovira i Pato Director of CERCA– Catalan Government Josep Maria Gómez Pallarès Manager of the University of Girona Josep Calbó Angrill Vice-Dean for Research at the University of Girona Vicenç Martínez Ibáñez Catalan Health Institute (ICS) Regional Manager for Girona Joan Profitós Tuset President IAS (Healthcare Institute) Girona
Albert Barberà Lluís Director of the IDIBGI
11
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
INTRODUCTION
SCIENTIFIC ADVISORY BOARD
INTERNAL SCIENTIFIC COMMITTEE
MEMBERS Silva Arslanian Pediatric Clinical & Translational Research Center, Children’s Hospital of Pittsburgh Angelo Barbato Istituto di Ricerche Farmacologiche Mario Negri, Milan Angel Carracedo Genomic Medicine, University of Santiago de Compostela Josep Figueras European Observatory on Health Systems and Policies, World Health Organization, Brussels Carlos Kase Department of Neurology, Boston Medical Center Blanca Marín University of Navarra, Pamplona Luis Martí-Bonmatí Radiology Department of the Hospital Quirón, Valencia Mike Pringle Royal College of General Practitioners (RCGP), UK Walter A Rocca Epidemiology and Neurology Department, Health Sciences Research Department, Neurology Mayo Clinic, Rochester, Minnesota Marisol Soengas Molecular Pathology Programme, Spanish National Cancer Research Centre, Madrid
PRESIDENT Albert Barberà Lluís Director of the IDIBGI MEMBERS IAS Jordi Cid Mental Health Group Leader Josep Garre Aging and Health Group Leader ICS José Manuel Fernández-Real Nutrition, Eumetabolism and Health Group Leader Rafel Ramos Girona Heart Registry Group Leader Joaquín Serena Cerebrovascular Pathology Researcher Pilar Sole Coordinator of Research in Nursing of the University Hospital of Girona Montserrat Vendrell Bronquiectasys Group Leader ICO David Gallardo Hematology Group Leader Rafel Marcos-Gragera Descriptive epidemiology, genetics and cancer prevention Group Leader Begoña Martín ICO Clinical Research Unit Coordinator Javier Menéndez Molecular Oncology Group Leader IDI Salvador Pedraza Medical Imaging Group Leader UdG Ramon Brugada Cardiovascular Genetics Group Leader Dolors Juvinyà Health and Health Care Group Leader SECRETARY Guillem Pérez Sánchez Scientific Coordinator
12
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
13
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Facts and figures
14
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
FACTS AND FIGURES
Management report ANNUAL BUDGET 6.000.000 €
2010
2011
2012
2013
4.486.619,24 €
3.504.806,91 €
4.220.438,92 €
5.061.407,16 €
16
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
FACTS AND FIGURES
Funds sources and expenses
2013 Expenses Human Resources: 36,77 % Medical consumables: 23,22 % Collaborations: 4,81 % Publications & academic training: 2,90 % Travelling costs: 2,21 % Other Services: 3,79 % Collaborations with other institutions: 3,47 % Equipment: 4,92 % Institutional Running costs: 5,79 % Administration office: 8,15 % Research support: 3,97 %
2013 Funds Origin Pharmaceutical companies: 19,11 % Donations: 2,99 % Other privat funds: 5,31 % ISCIII: 32,88 % MICINN: 6,39 % Other public funds: 2,69 % Generalitat de Catalunya: 8,89 % La Caixa Foundation: 10,87 % Other associations & foundations: 2,20 % European funds (FP7-EU): 4,54 % Finantial income: 4,13 %
17
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
FACTS AND FIGURES
SCIENTIFIC REPORT Number of articles
Q1
Q1
Q1
Q1
Q1
2009
2010
2011
2012
2013
46,75 %
169
54,19 %
179
55,63 %
160 18
56,44 %
202 ANNUAL SCIENTIFIC REPORT IDIBGI 2013
48,53 %
204
FACTS AND FIGURES
Articles by area
Cardiovascular 2009
2010
2011
2012
2013
2009
2010
2011
2012
2013
2009
2010
2011
2012
2013
24 22
27
17
22
Metabolism
31
38
28
32
27
Neurosciences
34 27 19
22
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
42 50
FACTS AND FIGURES
Articles by area
Oncology
2009
2010
2011
2012
2013
2009
2010
2011
2012
2013
54 69 50 71
53
Others
36 33 20
33
52 63
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
FACTS AND FIGURES
Impact Factor PER ARTICLE
2009 > 169
4,60
2010 > 179
4,64
2011 > 160
4,16 21
2012 > 202
4,51
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
2013 > 204
5,04
FACTS AND FIGURES
CLINICAL IMPACT
“Guía de Investigación Clínica 2013. Aspectos éticos y jurídicos a tener en cuenta en estudios clínicos en fase II y III” Secundi López-Pousa i Dolors Juvinjà. Càtedra de Promoció de la Salut de la Universitat de Girona: Documentació Universitaria. “Clinical practice guidelines in intracerebral haemorrhage” Rodríguez-Yáñez M, Castellanos M, Freijo MM, López Fernández JC, Martí-Fàbregas J, Nombela F, Simal P, Castillo J; Comitéad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la SEN, Díez-Tejedor E, Fuentes B, Alonso de Leciñana M, Alvarez-Sabin J, Arenillas J, Calleja S, Casado I, Dávalos A, Díaz-Otero F, Egido JA, Gállego J, García Pastor A, Gil-Núñez A, Gilo F, Irimia P, Lago A, Maestre J, Masjuan J, Martínez-Sánchez P, Martínez-Vila E, Molina C, Morales A, Purroy F, Ribó M, Roquer J, Rubio F, Segura T, Serena J, Tejada J, Vivancos J.. Neurologia. 2013;28:236-49. PMID: 21570742.
Fernández F, Ibáñez V, Lozano F, March JR, Romera A, Almenar L, Castro A, Escribano P, Lázaro M, Luis Zamorano J, Alonso JR, Ramón Casal J, Miguel Franco J, Jiménez S, Merlo M, Perales R, Piñera P, Ruiz-Artacho P, Suero C, Barba R, Fernández-Capitán C, García-Bragado F, Gómez V, Monreal M, Nieto JA, Riera-Mestre A, Suárez C, Trujillo-Santos J, Conget F, Jara L, Jiménez D, Lobo JL, de Miguel J, Nauffal D, Oribe M, Otero R, Uresandi F, Domenech P, González-Porras JR, Lecumberri R, Llamas P, Mingot E, Pina E, RodríguezMartorell J; : Spanish Society of Pneumology and Thoracic Surgery (SEPAR); Society Española Internal Medicine (SEMI); Spanish Society of Thrombosis and Haemostasis (SETH); Spanish Society of Cardiology (ESC); Spanish Society of Medicine Accident and Emergency (SEMES); Spanish Society of Angiology and Surgery Vascular (SEACV). Archivos de Bronconeumologia. 2013;49:534-47. PMID: 24041726
“Técnicas manuales e instrumentales para el drenaje de secreciones bronquiales en el paciente adulto” Montserrat Vendrell. Manual Separ de procedimientos. “Cuantificación ultranosográfica de la estenosis carotídea: recomendaciones de la Sociedad Española de Neurosonología (SONES)” Serena J, Irimia P, Calleja S, Blanco M, Vivancos J, Ayo-Martín O; en representación de la Sociedad Española de Neurosonología (SONES). Neurologia 2013;28:435-42. PMID: 23040716. “Pautes per a l’harmonització del tractament farmacològic de la diabetis mellitus tipus 2” Fau E, Mata M, Morros R, Pellicer MA, Ricart W, Vallès JA, Zafon C. Servei Català de la Salut. Departament de Salut-Generalitat de Catalunya. “National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism. Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Society Española Internal Medicine (SEMI). Spanish Society of Thrombosis and Haemostasis (SETH). Spanish Society of Cardiology (ESC). Spanish Society of Medicine Accident and Emergency (SEMES). Spanish Society of Angiology and Surgery Vascular (SEACV)”. Uresandi F, Monreal M, García-Bragado F, Domenech P, Lecumberri R, Escribano P, Zamorano JL, Jiménez S, Ruiz-Artacho P, Lozano F, Romera A, Jiménez D; National Consensus on Diagnosis, Risk Stratification and Treatment of Patients With Pulmonary Thromboembolism, Bellmunt S, Cuenca J, Fernández Á,
22
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
FACTS AND FIGURES
THESES
Title Title Descripció, evolució i possibles causes de la mortalitat Projecte EM-Line!: Programa de rehabilitación cognitiva al Sudoest d’Espanya: un anàlisi des de l’epidemiologia para pacientes afectados de esclerosis múltiple. geogràfica. Doctorate Thesis Reader Doctorate Thesis Reader Jordi Gich Maria Buxó University
University
Universitat de Girona.
Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut
Title Title Classificació del subtipus de fibromialgia d’acord amb Estratègies de diagnòstic genètic en fetus amb la simptomatologia clínica i anàlisis de les diferències de malformacions congènites. Correlació genotip-fenotip. personalitat, psicopatologia concomitant i qualitat de vida percebuda. Doctorate Thesis Reader Doctorate Thesis Reader Irene Mademont Dagmar Keller University University
Universitat de Barcelona
Universitat de Girona Departament de Psicologia
Title Mecanismos de Resistencia a Fármacos Anti-Receptores de la familia HER: desarrollo y caracterización “Ómica” de modelos tumorales in vitro. Doctorate Thesis Reader Cristina Oliveras University Universitat de Girona Facultat de Biología
23
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
FACTS AND FIGURES
CLINICAL TRIALS
APPROVED AND SIGNED IN 2013
43
45
51
60
65
Total of Studies Signed
30
30
28
27
37
Clinical Trials
2009
2010
2011
2012
2013
CLINICAL TRIALS BY PHASE 2009-2013
PHASE I PHASE II PHASE III PHASE IV
In 2013, a total of 222 clinical studies were carried out at our institution (5 led by IDIBGI researchers)
2009
1 9 19 1
2010
0 13 14 2
2011
0 9 17 2 24
2012
1 11 14 1
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
2013
1 12 22 2
FACTS AND FIGURES
This list reflects all the journals in which investigators of the IDIBGI have published articles during 2013. The journals on Decile 1 are highlighted.
JOURNAL IF Total Articles QUARTILE Published Acta Diabetologica Addictive Behaviors Age and Ageing AIDS Research and Therapy American Journal of Forensic Medicine and Pathology American Journal of Geriatric Psychiatry American Journal of Hematology American Journal of Hypertension American Journal of Medicine American Journal of Physiology-Heart and Circulatory Physiology American Journal of Respiratory and Critical Care Medicine Annals of Oncology Archives of Clinical Neuropsychology Archivos de Bronconeumología Atherosclerosis Autophagy Biomedical Signal Processing and Control Biomolecular NMR Assignments Blood BMC Nephrology BMC Neurology BMC Public Health Bone Marrow Transplantation Breast British Journal of Haematology Cancer Epidemiology Cardiology in the Young Cardiovascular Pathology Cell Cycle Chest Clinical and Applied Thrombosis-Hemostasis Clinical and Translational Oncology Clinical Cardiology Clinical Chemistry Clinical Infectious Diseases Clinical Microbiology and Infection Critical Care Medicine Current Medical Research and Opinion Current Medicinal Chemistry Dementia and Geriatric Cognitive Disorders Diabetes Diabetologia Enfermería Clinica Environmental Health Perspectives Epilepsia Epilepsy Research Europace European Journal of Cancer European Journal of Clinical pharmacology European Journal of Haematology European Journal of Human Genetics
3.68 1 2 2.44 1 1 3.11 1 1 1.84 1 4 0.62 1 3 3.52 1 1 3.48 1 2 3.40 1 2 5.30 1 1 4.01 1 1 11.99 1 1 6.58 1 1 1.92 1 3 1.82 1 3 3.97 1 1 11.42 1 1 1.53 2 3 0.82 1 4 9.78 2 1 1.52 1 3 2.49 1 2 2.32 1 2 3.47 1 2 2.58 1 1 4.96 1 1 2.56 2 3 0.86 1 4 2.34 1 2 5.01 8 2 7.13 1 1 1.58 1 3 1.60 1 4 2.23 1 2 7.77 1 1 9.42 1 1 5.20 2 1 6.15 1 1 2.37 1 1 3.72 1 1 2.81 1 2 8.47 2 1 6.88 1 1 - 1 7.03 1 1 4.58 1 1 2.19 1 2 3.05 1 2 4.82 1 1 2.70 1 2 2.41 1 3 4.23 1 1
25
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
FACTS AND FIGURES
JOURNAL IF Total Articles QUARTILE Published European Journal of Medical Genetics European Journal of Paediatric Neurology EuropeanRadiology European Spine Journal Febs Journal Febs Letters Fertility and Sterility Food and Chemical Toxicology Food Chemistry Forensic science international-genetic supplement series Gaceta Aanitaria Gastroenterología y Hepatología Gestión y Evaluación de Costes Sanitarios Gynecologic Oncology Haematologica-The Hematology Journal Health & Place Hipertensión y Riesgo Vascular Hormone and Metabolic Research Human Immunology Human Mutation Human Vaccines & Immunotherapeutics IEEE Journal of Biomedical and Health Informatics IEEE Transactions on Biomedical Engineering Influenza and Other Respiratory Viruses Insights Into Imaging Intensive Care Medicine International Journal of Biochemistry & Cell Biology International Journal of Cancer International Journal of Geriatric Psychiatry International Journal of Neuroscience International Journal of Obesity International Journal of Stroke Journal of Alzheimers Disease Journal of Cancer Journal of Cerebral Blood Flow and Metabolism Journal of Clinical Endocrinology & Metabolism Journal of Electrocardiology Journal of Epidemiology and Community Health Journal of Geriatric Psychiatry and Neurology Journal of Medical Genetics Journal of Molecular Medicine Journal of Neurology, Neurosurgery and Psychiatry Journal of Nutritional Biochemistry Journal of Psychosomatic Research Journal of Separation Science Journal of Social Research & Policy Journal of Stroke & Cerebrovascular Diseases Journal of the American Geriatrics Society Journal of the American Society of Nephrology Journal of Ultrasound in Medicine Kidney International
1.49 1 4 1.93 1 3 4.34 1 1 2.47 1 2 3.99 1 2 3.34 1 2 4.30 1 1 2.61 2 1 3.26 1 1 - 1 1.25 2 3 0.83 1 4 - 1 3.69 1 1 5.87 3 1 2.44 1 1 - 1 2.04 1 3 2.28 1 3 5.05 1 1 2.13 1 2 - 1 2.23 2 2 1.90 2 3 - 1 6.15 1 1 4.24 1 2 5.01 1 1 3.09 2 2 1.53 1 4 5.39 4 1 4.03 1 2 3.61 2 2 2.64 1 3 5.34 1 1 6.31 4 1 1.36 1 3 3.29 1 1 1.63 1 3 5.64 1 1 4.74 1 1 5.58 1 1 4.59 1 1 2.84 1 2 2.59 1 2 - 1 0 1.99 1 3 4.22 1 1 9.47 1 1 1.53 1 2 8.52 1 1
26
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
FACTS AND FIGURES
JOURNAL IF Total Articles QUARTILE Published Lancet Leukemia Mediators of Inflammation Medical Hypotheses Medical Image Analysis Medicina Clínica Medicina Intensiva Multiple Sclerosis Journal Nefrologia Neurology New England Journal of Medicine Oncology Letters Oncotarget Patient Preference and Adherence Pediatric Infectious Disease Journal Placenta Plos One Preventive Medicine RenalFailure Respiratory Medicine Respiratory Research Revista Clínica Española Revista de Neurologia Revista Española de Cardiología Revista Española de Cardiología Revista Panamericana de Salud Pública Scientific Reports Rocial Indicators Research Social Networks Stroke Thrombosis and Haemostasis Thrombosis Research
39.21 1 1 9.38 2 1 2.42 2 3 1.15 1 4 3.68 1 1 1.25 2 3 1.24 6 4 4.86 2 1 1.44 6 4 8.30 1 1 54.42 5 1 0.99 1 4 6.63 1 1 1.33 1 2 3.14 1 1 3.29 1 1 3.53 11 1 2.93 1 1 0.78 1 4 2.92 1 2 3.38 1 2 1.31 2 3 0.93 5 4 3.34 2 2 3.34 1 2 0.72 1 4 5.08 3 1 1.45 1 1 2.14 1 1 6.02 7 1 5.76 2 1 2.43 2 3
27
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEWS
NEWS 2013 January 2013
March 2013
Radiòlegs de l’IDIBGI lideren una recerca pionera en la delimitació de tumors cerebrals molt agressius
Investigadors de l’IDIBGI posen en marxa una nova estratègia de tractament per a pacients que han patit un ictus mentre dormien
L’estudi s’acaba de publicar a la prestigiosa revista European Radiology
Aquest nou procediment s’emmarca dins el projecte europeu WAKE UP, del qual l’Hospital Universitari de Girona Doctor Josep Trueta és el centre coordinador a tot l’Estat espanyol.
Grup de Recerca en Imatge Mèdica i del departament de Radiologia de l’IDI (Institut de Diagnòstic per la Imatge), de l’Hospital Universitari Dr. Josep Trueta de Girona
Grup de Recerca en Imatge Mèdica del departament de Radiologia-IDI (Institut de Diagnòstic per la Imatge) i investigadors del grup de recerca en patologia vascular cerebral del servei de Neurologia, de l’Hospital Universitari de Girona Doctor Josep Trueta
Principals mitjans: TV3, El 9 Diari, Catalunya Press, El Punt Avui, Europa Press, La Voz Libre, Diario Médico, Ara Girona, Diari de Girona, Agència Catalana de Notícies (ACN), 20 minutos, La Vanguardia, Vilaweb...
Principals mitjans: Catalunya Ràdio, TV Girona, Informativos Telecinco, 20 minutos, Diari de Girona, El Confidencial, El Economista, Europa Press, La Vanguardia, Canarias 7, Gente Digital, Interbusca, La información, MedicinaTV, Redacción Médica, Salud Digestivo, Siete días Médicos, Siglo XXI, Agència Catalana de Notícies (ACN)...
February 2013
Una investigació de l’IDIBGI confirma que l’apatia clínica significativa fa augmentar el risc de mortalitat en els malats d’Alzheimer
L’estudi, el més complet sobre l’apatia en l’Alzheimer dut a terme a l’Estat espanyol, s’ha publicat a la prestigiosa revista Journal of Alzheimer Disease. Grup de Recerca en Imatge Mèdica i del departament de Radiologia de l’IDI (Institut de Diagnòstic per la Imatge), de l’Hospital Universitari Dr. Josep Trueta de Girona Principals mitjans: Ara Girona, Diari de Girona, El 9 Diari, La Vanguardia...
28
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEWS
May 2013
May 2013
Un nou estudi de l’IDIBGI permet augmentar la precisió diagnòstica en casos d’infarts cerebrals que afecten el tracte corticoespinal
El Centre de Genètica Cardiovascular de l’IDIBGI obté dues beques de recerca pel seu projecte sobre la mort sobtada
La investigació, pionera a nivell mundial, ha estat publicada a la prestigiosa revista americana Stroke.
El Dr. Ramon Brugada, director del centre, també ha estat guardonat pel DVD "Salvar una vida no té preu"
Grup de Recerca en Imatge Mèdica i del departament de Radiologia de l’IDI (Institut de Diagnòstic per la Imatge), de l’Hospital Universitari Dr. Josep Trueta de Girona
Centre de Genètica Cardiovascular Principals mitjans: Diari de Girona, El Punt/Avui
Principals mitjans: 20 minutos, Canarias 7, Diari de Girona, El Confidencial, El Economista, Europa Press, Gente Digital, Informativos Telecinco, Interbusca, La Información, La Vanguardia, Medicina TV, Redacción Médica, Salud Digestivo, Siete Días Médicos, Siglo XXI, Ara Girona, Diari de Girona, Terra España, TV Girona
June 2013
El Doctor Lisardo Boscà, un dels grans investigadors del nostre país, analitzarà els reptes de futur de la investigació en salut dins els Seminaris de l’IDIBGI
May 2013
Un equip de l’IDIBGI, premiat per la versió espanyola del “Leicester Cough Questionnaire”
Boscà és subdirector General d’Avaluació i Foment de la Investigació de l’Instituto de Salud Carlos III, el principal ens d’investigació biomèdica d’Espanya Principals mitjans: Diari de Girona, El Punt/Avui Va aconseguir el 2n premi de Fisioteràpia i Infermeria a la XXXI Diada Pneumològica celebrada a Sitges Grup de Recerca en Imatge Mèdica i del departament de Radiologia de l’IDI (Institut de Diagnòstic per la Imatge), de l’Hospital Universitari Dr. Josep Trueta de Girona Principals mitjans: Diari de Girona, RDI Press
29
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEWS
September 2013
October 2013
Albert Barberà: «La recerca que fem ha de superar el complex de província; estem deixant una petjada al món»
El doctor Josep Puig Alcántara, radiòleg de l’IDBIGI, rep el premi anual a la investigació de la Sociedad Española de Neurorradiología
Entrevista a Albert Barberà, director de l’IDIBGI
El jurat ha valorat, entre d’altres, tres investigacions del doctor Josep Puig per millorar la precisió diagnòstica de l’infart i el tumor cerebral
Diari de Girona
Principals mitjans: Diari de Girona, El Punt/Avui
October 2013
L’IDIBGI posa en marxa el primer Biobanc de les comarques gironines
December 2013
Investigadors de l’IDIGBI fan el primer estudi comparatiu sobre la composició del greix subcutani i visceral
La finalitat d’aquest organisme és recollir i emmagatzemar mostres biològiques humanes per facilitar els projectes d’investigació Principals mitjans: 20 minutos, ACN (Agència Catalana de Notícies), Actualidades, Ara, Diari de Girona, Ecodiario, El Economista, El Punt/Avui, Europa Press, Gente Digital, Lo Campus Diari, TV3 i 3/24, Vilaweb, La Información, La Vanguardia, Press People, TV Girona, Cadena SER (entrevista a l’Aina Rodríguez Vilarupla, coordinadora del Biobanc, a l’Hora L Girona)
30
L’estudi ha estat publicat recentment a la prestigiosa revista americana FASEB Journal Principals mitjans: Informativos Telecinco, Diari de Girona, 20 minutos, Estar Bien, Gaceta Médica, EFEsalud, Europapress, El Economista, Ecodiario, Crónica de Cantabria, La Información, Infosalus, Infodoctor, Medicina TV, Especialista em saúde, Siglo XXI, Yahoo News, La Voz Libre, Jano.ES, Innovaticias.
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Cardiovascular Area CARDIOVASCULAR GENETICS GIRONA HEART REGISTRY (REGICOR)
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
CARDIOVASCULAR AREA
The investigators at Gencardio we have actively participated in the field of Sudden Cardiac Death (SCD) for more than 20 years through clinical research as well as basic research in genetics, molecular biology, biophysics and biochemistry. Our expertise in all clinical aspects of SCD and arrhythmias has enabled our group to lead some of the most important discoveries in this field.
34
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
CARDIOVASCULAR AREA
CARDIOVASCULAR GENETICS Group members
Group Leader: Ramon Brugada
Post-doctorate researchers
— Catarina Allegue — Pedro Beltrán — Oscar Campuzano — Sara Pagans — Guillermo Pérez — Fabiana Scornik — Elisabet Selga — Marcel Verges
Post-graduate researchers — Mireia Alcalde — Bruna Barras — Cristina Bosch — Monica Coll — Jesus Matés — Javier Moncayo — Helena Riuró — Olallo Sánchez — Anna Tarradas
Technicians — Irene Mademont — Alexandra Pérez — Ferran Picó
Support — Anna Iglesias
Strategic objectives
Main line of research
Reference centre on a Spanish level for genetic research and analysis of pathologies associated with Sudden Cardiac Death.
Genetic and molecular basis of Sudden Cardiac Death.
35
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
CARDIOVASCULAR AREA
Publications
Iglesias A, Pisani D, Pascali VL, Paolino MC, Villa MP, Zara F, Tassinari CA, Striano P, Brugada R. “Coexistence of epilepsy and Brugada syndrome in a family with SCN5A mutation”. Epilepsy Research 2013; 105:415-8. PMID: 23538271. I.F.: 2,19.
Originals (I.F.: 37,77): 1. Campuzano O, Alcalde M, Berne P, Zorio E, Iglesias A, Navarro-Manchón J, Brugada J, Brugada R. “Role of novel DSP_p.Q986X genetic variation in arrhythmogenic right ventricular cardiomyopathy”. European Journal of Medical Genetics. 2013; 56:541-5. PMID: 23954618. I.F.: 1,49.
9. Gurrieri F, Zollino M, Oliva A, Pascali V, Orteschi D, Pietrobono R, Camporeale A, Coll Vidal M, Partemi S, Brugada R, Bellocci F, Neri G. “Mild Beckwith-Wiedemann and severe long-QT syndrome due to deletion of the imprinting center 2 on chromosome 11p”. European Journal of Human Genetics. 2013; 21:965-9. PMID: 23511928. I.F.: 4,23.
2. Beltrán-Álvarez P, Espejo A, Schmauder R, Beltrán C, Mrowka R, Linke T, Batlle M, Pérez-Villa F, Pérez GJ, Scornik FS, Benndorf K, Pagans S, Zimmer T, Brugada R. “Protein arginine methyl transferases-3 and -5 increase cell surface expression of cardiac sodium channel”. FEBS Letters. 2013; 587:3159-65. PMID: 23912080. I.F.: 3,34. 3. Partemi S, Cestèle S, Pezzella M, Campuzano O, Paravidino R, Pascali VL, Zara F, Tassinari CA, Striano S, Oliva A, Brugada R, Mantegazza M, Striano P. “Loss-offunction KCNH2 mutation in a family with long QT syndrome, epilepsy, and sudden death”. Epilepsia. 2013; 54:e112-6. PMID: 23899126. I.F.: 4,58. 4. Brugada J, Blom N, Sarquella-Brugada G, BlomstromLundqvist C, Deanfield J, Janousek J, Abrams D, Bauersfeld U, Brugada R, Drago F, de Groot N, Happonen JM, Hebe J, Yen Ho S, Marijon E, Paul T, Pfammatter JP, Rosenthal E. “Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPCArrhythmia Working Group joint consensus statement”. Europace. 2013; 15:1337-82. PMID: 23851511. I.F.: 3,05.
10. Tarradas A, Selga E, Beltrán-Álvarez P, Pérez-Serra A, Riuró H, Picó F, Iglesias A, Campuzano O, Castro-Urda V, Fernández-Lozano I, Pérez GJ, Scornik FS, Brugada R. “A novel missense mutation, I890T, in the pore region of cardiac sodium channel causes Brugada syndrome”. PLoS One. 2013; 8:e53220. PMID: 23308164. I.F.: 3,53. 11. Moya A, Sancho-Tello MJ, Arenal A, Fidalgo ML, Brugada R, Martínez Ferrer J, Merino JL, Ruiz Mateas F, Mont JL. “Innovations in heart rhythm disturbances: cardiac electrophysiology, arrhythmias, and cardiac pacing”. Revista Española de Cardiología. 2013; 66:116-23. PMID: 23201349. I.F.: 3,34. 12. Partemi S, Batlle M, Berne P, Berruezo A, Campos B, Mont L, Riuró H, Roig E, Pérez-Villa F, Ortiz J, Pascali VL, Oliva A, Brugada R, Brugada J. “Analysis of the arrhythmogenic substrate in human heart failure”. Cardiovascular Pathology. 2013; 22:133-40. PMID: 23036686. I.F.: 2,34.
5. Oliva A, Partemi S, Pascali VL, Brugada R. “Genetic causes of sudden infant death syndrome: a postmortem investigation not to be missed”. American Journal of Forensic Medicine and Pathology. 2013; 34:e3. PMID: 23574868. I.F.: 0,62. 6. Riuró H, Beltran-Alvarez P, Tarradas A, Selga E, Campuzano O, Vergés M, Pagans S, Iglesias A, Brugada J, Brugada P, Vázquez FM, Pérez GJ, Scornik FS, Brugada R. “A missense mutation in the sodium channel β2 subunit reveals SCN2B as a new candidate gene for Brugada syndrome”. Human Mutation. 2013; 34:961-6. PMID: 23559163. I.F.: 5,05. 7. Scornik FS, Bucciero RS, Wu Y, Selga E, Bosch Calero C, Brugada R, Pérez GJ. “DiBAC₄(3) hits a “sweet spot” for the activation of arterial large-conductance Ca²+-activated potassium channels independently of the β₁-subunit”. American Journal of Physiology-Heart and Circulation Physiology. 2013; 304:H1471-82. PMID: 23542916. I.F.: 4,01.
13. S. Partemi, M. Coll Vidal, O. Campuzano, M. Pezzella, R. Paravidino, V.L. Pascali, C.A. Tassinari, S. Striano, F. Zara, R. Brugada, P. Striano, A. Oliva. “Importance of postmortem genetic testing in SUDEP patients”. Forensic Science International-Genetic Supplement Series. 2013; e354-e355. Editorial (I.F.: 1,36): 1. Noris M, Carrillo A, Campuzano O, Santaella A, Brugada R, García-Niebla J, Fiol M. “Syncope and polymorphic ventricular tachycardia in the setting of a febrile illness”. Journal of Electrocardiology. 2013; 46:666-9. PMID: 23522323. I.F.: 1,36. Reviews (I.F.: 6.49): 1. Campuzano O, Alcalde M, Allegue C, Iglesias A, GarcíaPavía P, Partemi S, Oliva A, Pascali VL, Berne P, SarquellaBrugada G, Brugada J, Brugada P, Brugada R. “Genetics of arrhythmogenic right ventricular cardiomyopathy”. Journal of Medical Genetics. 2013; 50:280-9. PMID: 23468208. I.F.: 5,64.
8. Parisi P, Oliva A, Coll Vidal M, Partemi S, Campuzano O,
36
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
CARDIOVASCULAR AREA
2. Sarquella-Brugada G, Campuzano O, Iglesias A, SánchezMalagón J, Guerra-Balic M, Brugada J, Brugada R. “Genetics of sudden cardiac death in children and young athletes”. Cardiology in the Young. 2013; 23:159-73. PMID: 22824130. I.F.: 0,86.
- Sudden cardiac death: Translating basic science into clinical care Grant: CNIC-TRANSLATIONAL 2008 Duration: 2009 – 2014 Ramon Brugada
Books:
- Genotipado de alto rendimiento en el diagnóstico genético del síndrome de Brugada. PI11/01826 Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2012 - 31/12/2014 Ramon Brugada
- Campuzano O, Brugada R. “Brugada Syndrome and related cardiac diseases”. On: Murray M, Giovanni M, Babyatsky M W. “Clinical Genomics: Practical Application in Adult Patient Care”. Mc Graw Hill, 2013. Chapter 22; pp 107110. - Campuzano O, Allegeu C, Brugada R. “Genètica de la mort sobtada cardíaca” Revista CBCAT (Col·legi Oficial de Biòlegs de Catalunya), 2013. - Campuzano O, Sarquella-Brugada G, Brugada R, Brugada J, Brugada P. Chapter: Brugada Syndrome. Editor: eLS, Wiley Online Library, 2013
Grants for research in progress: - RED DE ENFERMEDADES CARDIOVASCULARES RD12/0042/0059 Sponsored by: Instituto de Salud Carlos III Duration: 2013 Ramon Brugada
- Ayudas predoctorales de formación en investigación en salud. FI10/00453 Sponsored by: Instituto de Salud Carlos III Duration: 01/09/2010 - 31/12/2014 Ramon Brugada Beneficiary: Cristina Bosch - Mort sobtada infantil: diagnòstic genètic mitjançant tecnologia d’ultrasequenciació (next generation sequencing, NGS) Sponsored by: Societat Catalana Cardiologia Duration: 16/07/2012 - 16/07/2014 Ramon Brugada - Contrato postdoctoral Sara Borrell (CD10/00275) Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2011 - 31/12/2013 Ramon Brugada Beneficiary: Pedro Beltrán
- Muerte súbita infantil: diagnóstico genético mediante tecnología de ultrasecuenciación next generation sequencing NGS Grant: Convocatoria ayudas 2012 - Fundacion Eugenio Rodriguez Pascual Duration: 01/03/2013 – 01/03/2014 Ramon Brugada - Traslación de tecnología genética innovadora al diagnóstico de enfermedades hereditarias relacionadas con la muerte súbita inexplicada. Sponsored by: Ministerio de Ciencia e Innovación. Subprograma INNPACTO 2010 Duration: 2010-2013 Consorcio Gendiag.exe - Ramon Brugada - Suport Grups de Recerca Emergent (GRE) (2009-SRG/ DGR-0712) Grant: Dirección General de Recerca (DGR) de la Generalitat de Catalunya Duration: 2009 - 2013 Ramon Brugada
37
- Mort Sobtada Inexplicada a Catalunya: valoració clínica i genètica. Sponsored by: Fundació Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears. Duration: 2013-2014 Ramon Brugada - Muerte súbita infantil: diagnóstico genético mediante tecnología de ultrasecuenciación (next generation sequencing, NGS). Sponsored by: Fundación Eugenio Rodríguez Pascual Duration: 2013-2014 Ramon Brugada - Estudio de los mecanismos moleculares que regulan la expresión y función de SCN5A (SAF2011-27627) Sponsored by: Ministerio de Economía y Educación. Investigación fundamental no orientada Duration: 2012 - 2014 Sara Pagans
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
CARDIOVASCULAR AREA
The main line of research of the group is to improve the detection and control of patients with intermediate cardiovascular risk and the detection of CV disease in the asymptomatic phase and analyse the cost effectiveness of the actions taken for the prevention of cardiovascular disease.
38
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
CARDIOVASCULAR AREA
GIRONA HEART REGISTRY (REGICOR) Group members
Group Leader: Joan Sala Group Leader: Rafael Ramos
Post-graduate researchers
Medical researchers
Technicians
— Jaime Aboal — Xavier Albert — Elisabet Balló — Daniel Bosch — Carlos Cerezo — Pablo de Loma-Osorio — Miquel Quesada — Pascual Solanas
— Maria del Mar Garcia
— Ruth Martí — Anna Ponjoan
Strategic objectives
Main line of research
1. Analyse the role of emerging risk factors and asymptomatic atherosclerosis as well as the co-morbidity of the patient in the prediction of cardiovascular risk. 2. Develop cardiovascular risk functions adapted to specific subpopulation groups (diabetes, patients with a family history of vascular disease, obesity). 3. Evaluate the effectiveness and efficiency of different actions for the prevention and control of atherosclerotic disease in Primary Healthcare using the Information System for the Development of Research in Primary Care (SIDIAP). 4. Analyse the role of CV risk factors and their control in the incidence of dementias.
The main line of research of the group is to improve the detection and control of patients with intermediate cardiovascular risk and the detection of CV disease in the asymptomatic phase and analyse the cost effectiveness of the actions taken for the prevention of cardiovascular disease.
39
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
CARDIOVASCULAR AREA
Publications
Grants for research in progress:
Originals (I.F.: 22,40): 1. Ariza-Solé A, Formiga F, Vidán MT, Bueno H, Curós A, Aboal J, Llibre C, Rueda F, Bernal E, Cequier A. “Impact of frailty and functional status on outcomes in elderly patients with STsegment elevation myocardial infarction undergoing primary angioplasty: rationale and design of the IFFANIAM study.” Clinical Cardiology 2013; 36:565-9. PMID: 24114768. I.F.: 2,23. 2. Loma-Osorio P, Aboal J, Sanz M, Caballero A, Vila M, Lorente V, Sánchez-Salado JC, Sionis A, Curós A, Lidón RM. “Clinical Characteristics and Vital and Functional Prognosis of Out-of-hospital Cardiac Arrest Survivors Admitted to Five Cardiac Intensive Care Units.” Revista Española de Cardiología 2013; 66:623-8. PMID: 23830835. I.F.: 3,34.
- Avances en el manejo el riesgo intermedio. Estudio MARK (improving interMediAte RisK management) (PI10/01088) Sponsored by: Instituto de Salud Carlos III Duration: 2011 - 2013 Rafel Ramos - Determinantes genéticos y ambientales de la disfunción vascular en la hipertensión y en la cardiopatía isquémica: Red HERACLES (RD06/0009/1004) Sponsored by: Instituto de Salud Carlos III Duration: 01/01/2008 - 31/12/2013 Joan Sala - Efectividad del Inicio del Tratamiento Antihipertensivo en la Prevención Primaria de Eventos Cardiovasculares. Proyecto EITEC. (PI12/00052) Sponsored by: Instituto de Salud Carlos III Duration: 2012 - 2014 Mar García
3. Grau M, Baena-Díez JM, Félix-Redondo FJ, FernándezBerges D, Comas-Cufí M, Forés R, Marrugat J, Ramos R. “Estimating the risk of peripheral artery disease using different population strategies.” Preventive Medicine 2013; 57:328-33. PMID: 23769902. I.F.: 2,93. 4. Agüero F, Dégano IR, Subirana I, Grau M, Zamora A, Sala J, Ramos R, Treserras R, Marrugat J, Elosua R. “Impact of a partial smoke-free legislation on myocardial infarction incidence, mortality and case-fatality in a population-based registry: the REGICOR Study.” PLoS One. 2013; 8:e53722. PMID: 23372663. I.F.: 3,53. 5. Sanchis J, Bardají A, Bosch X, Loma-Osorio P, Marín F, Sánchez PL, Calvo F, Avanzas P, Hernández C, Serrano S, Carratalá A, Barrabés JA. “N-terminal Pro-brain Natriuretic Peptide and High-sensitivity Troponin in the Evaluation of Acute Chest Pain of Uncertain Etiology. A PITAGORAS Substudy.” Revista Española de Cardiología 2013; 66:532-8. PMID: 23369873. I.F.: 3,34.
- Efectividad de las Estatinas en población de Edad avanzada en España. Estudio 4E Sponsored by: Ministerio de Sanidad y Política Social e Igualdad. EC11-267 Duration: 2011 - 2013 Rafel Ramos - El Rol de las Estatinas en Prevención Primaria de Eventos Cardiovasculares en población con Enfermedad Renal Crónica (ERC). Proyecto ECERC Sponsored by: Ministerio de Sanidad y Política Social e Igualdad. EC11-349 Duration: 2011 - 2013 Mar García
6. Rivera M, Basagaña X, Aguilera I, Foraster M, Agis D, de Groot E, Perez L, Mendez MA, Bouso L, Targa J, Ramos R, Sala J, Marrugat J, Elosua R, Künzli N. “Association between long-term exposure to traffic-related air pollution and subclinical atherosclerosis: the REGICOR study”. Environnmental Health Perspectives. 2013;121:223-30. PMID: 23384708. I.F.: 7,03.
40
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Metabolism Area Bronchiectasis NUTRITION, EUMETABOLISM AND HEALTH PEDIATRIC ENDOCRINOLOGY
42
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
43
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
The incidence of bronchiectasis has increased in recent years resulting in greater costs, including periods of hospitalization and the prescription of drugs. We study how the ELTGOL technique (Slow Expiration With Glottis Opened in Lateral Posture) improves mucociliary clearance in adult patients with bronchiectasis.
44
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
Bronchiectasis Group members
Group Leader: Montserrat Vendrell
Post-graduate researchers — Gerard Muñoz
Publications
Grants for research in progress:
Originals (I.F.: 2,92):
- Estudio randomizado controlado con placebo para evaluar la eficacia de la técnica de drenaje de secreciones ELTGOL en pacientes con bronquiectasias Sponsored by: Instituto de Salud Carlos III Duration: 2013 - 2015 Montserrat Vendrell
1. de la Torre MC, Bolíbar I, Vendrell M, de Gracia J, Vendrell E, Rodrigo MJ, Boquet X, Torrebadella P, Yébenes JC, SerraPrat M, Rello J, Torres A, Almirall J. “Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia”. Respiratory Medicine. 2013; 107:2038-45. PMID: 24084059. I.F.: 2,92. Books: 1. Corral T, Herrero B, Muñoz G, Ríos AT. Técnicas manuales para el drenaje de secreciones bronquiales: Técnicas espiratorias lentas. Manual SEPAR de procedimientos “Técnicas manuales e instrumentales para el drenaje de secreciones bronquiales en el paciente adulto”. Barcelona. Editorial Respira. 2013 p. 27-39.
- Estudio randomizado controlado con placebo para evaluar la eficacia de la técnica de drenaje de secreciones ELTGOL en pacientes con bronquiectasias Sponsored by: Col legi Fisioterapeutes Catalunya Duration: 2013 - 2015 Montserrat Vendrell
2. Balañá A, Corral T, Marti JD, Mendez , Munoz G, Lopez D, Tomas A, Zuazagoitia JM. Técnicas instrumentales para el drenaje de secreciones bronquiales. Manual SEPAR de Procedimientos “Técnicas manuales e instrumentales para el drenaje de secreciones bronquiales en el paciente adulto” Barcelona. Editorial Respira. 2013. p. 65-94.
45
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
The idea is to reach to a critical combination of probiotics, prebiotics and innate immune proteins as therapeutic tools that will help in the prevention of type 2 diabetes and other obesity-associated metabolic complications. The increase in bacterial biodiversity could also result in weight loss.
46
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
NUTRITION, EUMETABOLISM AND HEALTH Group members Group Leader: José-Manuel Fernández-Real
Team involved in:
Post-doctorate researchers
Collaborators
— José María Moreno (CIBERobn) — Francisco José Ortega (CIBERobn) — Marta Serrano — María Moreno — Mar Rodríguez
Post-graduate researchers — Emili Loshuertos — Gemma Xifra
Medical researchers — Josefina Biarnés — Elisabet Costa — Eduardo Esteve — Merçè Fernández — Gemma Gifre — Sílvia Mauri — David Pérez — Inmaculada Recas — Mònica Recasens — Wifredo Ricart — Lídia Sojo
— Cristina Martínez
Technicians — Isabel Alonso — Mònica Sabater
Nursing staff — Oscar Rovira (CIBERobn)
Dietitan — Cristina Planella
Strategic objectives
Main line of research
- Microbiome Signature of metabolic diseases: Obesity Type-2 diabetes NASH - Circulating microRNA profile of metabolic diseases - Epigenomic Signature of metabolic diseases - Interaction between System Biology and Microbiome / miRNAs / Innate immune system
- Inflammation and insulin resistance. - Proteomics of the adipose tissue. - Metabolism of iron and insulin resistance. - Biomarkers for obesity, insulin resistance and Type-2 diabetes. - Bone as an endocrine organ. - Vascular disease and inflammation.
47
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
Publications
Fernández-García JC, Frühbeck G, Gómez-Ambrosi J, Menchón JM, Moragrega I, Rodríguez R, Tárrega S, Tinahones FJ, Fernández-Aranda F. “Modulation of the Endocannabinoids N-Arachidonoylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on Executive Functions in Humans.” PLoS One 2013; 8:e66387. PMID: 23840456. I.F.: 3,53.
Originals (I.F.: 100,03): 1. Serrano M, Moreno-Navarrete JM, Puig J, Moreno M, Guerra E, Ortega F, Xifra G, Ricart W, Fernández-Real JM. “Serum lipopolysaccharide-binding protein as a marker of atherosclerosis.” Atherosclerosis. 2013; 230:223-7. PMID: 24075748. I.F.:3,97. 2. Carson BP, Del Bas JM, Moreno-Navarrete JM, FernandezReal JM, Mora S. “The Rab11 Effector Protein FIP1 Regulates Adiponectin Trafficking and Secretion.” PLoS One. 2013; 8:e74687. PMID: 24040321. I.F.: 3,53. 3. Moreno-Navarrete JM, Escoté X, Ortega F, Serino M, Campbell M, Michalski MC, Laville M, Xifra G, Luche E, Domingo P, Sabater M, Pardo G, Waget A, Salvador J, Giralt M, Rodriguez-Hermosa JI, Camps M, Kolditz CI, Viguerie N, Galitzky J, Decaunes P, Ricart W, Frühbeck G, Villarroya F, Mingrone G, Langin D, Zorzano A, Vidal H, Vendrell J, Burcelin R, Vidal-Puig A, Fernández-Real JM. “A role for adipocytederived lipopolysaccharide-binding protein in inflammationand obesity-associated adipose tissue dysfunction”. Diabetologia. 2013; 56:2524-37.PMID: 23963324. I.F.: 6,88. 4. Moreno-Navarrete JM, Ortega F, Gómez-Serrano M, García-Santos E, Ricart W, Tinahones F, Mingrone G, Peral B, Fernández-Real JM. “The MRC1/CD68 ratio is positively associated with adipose tissue lipogenesis and with muscle mitochondrial gene expression in humans.” PLoS One 2013; 8:e70810. PMID: 23951013. I.F.: 3,53. 5. Prats-Puig A, Ortega FJ, Mercader JM, Moreno-Navarrete JM, Moreno M, Bonet N, Ricart W, López-Bermejo A, Fernández-Real JM. “Changes in circulating microRNAs are associated with childhood obesity.” Journal of Clinical Endocrinology & Metabolism 2013; 98:E1655-60. PMID: 23928666. I.F.: 6,31. 6. Carobbio S, Hagen RM, Lelliott CJ, Slawik M, MedinaGomez G, Tan CY, Sicard A, Atherton HJ, Barbarroja N, Bjursell M, Bohlooly-Y M, Virtue S, Tuthill A, Lefai E, Laville M, Wu T, Considine RV, Vidal H, Langin D, Oresic M, Tinahones FJ, Fernandez-Real JM, Griffin JL, Sethi JK, López M, Vidal-Puig A. “Adaptive Changes of the Insig1/SREBP1/SCD1 Set Point Help Adipose Tissue to Cope With Increased Storage Demands of Obesity.” Diabetes 2013; 62:3697-708. PMID: 23919961. I.F.: 8,47. 7. Fagundo AB, de la Torre R, Jiménez-Murcia S, Agüera Z, Pastor A, Casanueva FF, Granero R, Baños R, Botella C, Del Pino-Gutierrez A, Fernández-Real JM,
48
8. Pueyo N, Ortega FJ, Mercader JM, Moreno-Navarrete JM, Sabater M, Bonàs S, Botas P, Delgado E, Ricart W, MartinezLarrad MT, Serrano-Ríos M, Torrents D, Fernández-Real JM. “Common genetic variants of surfactant protein-D (SP-D) are associated with type 2 diabetes.” PLoS One 2013; 8:e60468. PMID: 23577114. I.F.: 3,53. 9. Fernández-Real JM, Puig J, Serrano M, Sabater M, Rubió A, Moreno-Navarrete JM, Fontan M, Casamitjana R, Xifra G, Ortega FJ, Salvador J, Frühbeck G, Ricart W. “Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations.” PLoS One 2013; 8:e58961. PMID: 23555610. I.F.: 3,53. 10. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, Ricart W, Fernández-Real JM. “Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance”. Journal of Clinical Endocrinology & Metabolism 2013; 98:E76978. PMID: 23436919. I.F.: 6,31. 11. Fernández-Real JM, Corella D, Goumidi L, Mercader JM, Valdés S, Rojo Martínez G, Ortega F, Martinez-Larrad MT, Gómez-Zumaquero JM, Salas-Salvadó J, Martinez González MA, Covas MI, Botas P, Delgado E, Cottel D, Ferrieres J, Amouyel P, Ricart W, Ros E, Meirhaeghe A, Serrano-Rios M, Soriguer F, Estruch R. “Thyroid hormone receptor alpha gene variants increase the risk of developing obesity and show gene-diet interactions”. International Journal of Obesity (London). 2013; 37:1499-505. PMID: 23399772. I.F.: 5,39. 12. Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N, Sabater M, Gómez-Ambrosi J, Anglada R, Fernández-Formoso JA, Ricart W, Frühbeck G, FernándezReal JM. “Targeting the circulating microRNA signature of obesity”. Clinical Chemistry. 2013; 59:781-92. PMID: 23396142. I.F.: 7,77. 13. Moreno-Navarrete JM, Serrano M, Sabater M, Ortega F, Serino M, Pueyo N, Luche E, Waget A, Rodriguez-Hermosa JI, Ricart W, Burcelin R, Fernández-Real JM. “Study of lactoferrin gene expression in human and mouse adipose tissue, human preadipocytes and mouse 3T3-L1 fibroblasts. Association with adipogenic and inflammatory markers”. Journal of Nutritional Biochemistry. 2013; 24:1266-75. PMID: 23333090. I.F.: 4,59.
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
Grants for research in progress:
14. Moreno-Navarrete JM, Touskova V, Sabater M, Mraz M, Drapalova J, Ortega F, Serrano M, Catalán V, GómezAmbrosi J, Ortiz MR, Pardo G, Pueyo N, Ricart W, Lacinova Z, Haluzik M, Frühbeck G, Fernández-Real JM. “Liver, but not adipose tissue PEDF gene expression is associated with insulin resistance”. International Journal of Obesity (London). 2013; 37:1230-7. PMID: 23318725. I.F.: 5,39. 15. Moreno-Navarrete JM, Petrov P, Serrano M, Ortega F, García-Ruiz E, Oliver P, Ribot J, Ricart W, Palou A, Luisa Bonet M, Fernández-Real JM. “Decreased RB1 mRNA, protein, and activity reflect obesity-induced altered adipogenic capacity in human adipose tissue”. Diabetes. 2013; 62:1923-31. PMID: 23315497. I.F.: 8,47. 16. Ortega FJ, Mercader JM, Moreno-Navarrete JM, Sabater M, Pueyo N, Valdés S, Ruiz B, Luche E, Serino M, Naon D, Ricart W, Botas P, Delgado E, Burcelin R, Frühbeck G, Bosch F, Mingrone G, Zorzano A, Fernández-Real JM. “Targeting the association of calgranulin B (S100A9) with insulin resistance and type 2 diabetes”. Journal of Molecular Medicine (Berlin). 2013; 91:523-34. PMID: 23207880. I.F.: 4,74. 17. Serino M, Fernández-Real JM, Fuentes EG, Queipo-Ortuño M, Moreno-Navarrete JM, Sánchez A, Burcelin R, Tinahones F. “The gut microbiota profile is associated with insulin action in humans”. Acta Diabetologica. 2013; 50:753-61. PMID: 22711164. I.F.: 4,63. 18. Cipollini M, Pastor S, Gemignani F, Castell J, Garritano S, Bonotti A, Biarnés J, Figlioli G, Romei C, Marcos R, Cristaudo A, Elisei R, Landi S, Velázquez A. “TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations”. International Journal of Cancer. 2013; 133:284351. PMID: 23754668. I.F.: 5,01. 19. Ortega FJ, Pueyo N, Moreno-Navarrete JM, Sabater M, Rodriguez-Hermosa JI, Ricart W, Tinahones FJ, FernándezReal JM. “The lung innate immune gene surfactant protein-D is expressed in adipose tissue and linked to obesity status”. International Journal of Obesity (London). 2013;37:1532-8. PMID: 23478426. I.F.: 5,39.
- MicroRNA circulantes y en tejido adiposo como biomarcadores metabólicos (PI11/00214) Sponsored by: Instituto de Salud Carlos III Duration: 2012 - 2015 J.M. Fernández-Real - The role of intestinal microflora in non-alcoholic fatty liver disease (FLORINASH) Sponsored by: European Commission. Seventh framework programme. Duration: 2010 - 2015 J.M. Fernández-Real (leader WP1) - CIBERobn. Centro de Investigación Biomédica en RedFisiopatologia de la Obesidad y Nutrición. Sponsored by: Instituto de Salud Carlos III Duration: 2006 ----J.M. Fernández-Real - Signatura microRNA DM-2 Sponsored by: Associació Catalana de Diabetis Duration: 2011 - 2013 J.M. Fernández-Real / Francisco José Ortega Delgado - Estudio del posible rol del hierro en la fisiología del tejido adiposo humano en asociación con obesidad y resistencia a la insulina Sponsored by: Instituto de Salud Carlos III Duration: 2012 - 2015 José Maria Moreno-Navarrete - Circulating microRNAS in prepubertal children as biomarkers of metabolic diseases as type 2 diabetes European Association for the Study of Diabetes Duration: 2013 - 2014 Francisco Ortega
Review (I.F.: 2,04): 1. Ortega FJ, Fernández-Real JM. “Inflammation in adipose tissue and fatty acid anabolism: when enough is enough!” Hormone and Metabolic Research. 2013;45:1009-19. PMID: 24277504. I.F.: 2,04.
49
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
Patents: - Authors: José Manuel Fernández-Real, Wifredo Ricart, Antonio Zorzano, Joan Vendrell, Abel López-Bermejo. Title: Use of soluble CD14 for treatment of diseases Patent number: PCT/EP2004/ 050189 Priority date: 2004 Assignee: Mellitus S.L. - Authors: José Manuel Fernández-Real, Wifredo Ricart, Antonio Zorzano, Joan Vendrell, Abel López-Bermejo. Title: Method for detecting a predisposition to develop gestational diabetes mellitus and treatment for this disease. Patent number: PCT/EP2004/104777.0 Priority date: 2004 Assignee: Mellitus S.L. - Authors: José Manuel Fernández-Real, Wifredo Ricart, Antonio Zorzano, Joan Vendrell, Abel López-Bermejo. Title: Use of BPI protein for the treatment of diseases. Patent number: EP05106245.3 Assignee: Mellitus S.L. - Authors: Francisco José Ortega Delgado, José Manuel Fernández-Real, Gemma Frühbeck, Josep Maria Mercader, Wifredo Ricart Title: Método para el diagnóstico y/o pronóstico de obesidad mórbida Patent number: ES2654.4 Assignee: CIBERobn, IDIBGI, Clínica Universidad de Navarra, Barcelona Supercomputing Center. - Authors: José Maria Moreno Navarrete, José Manuel Fernández-Real, Francesc Villarroya, Wifredo Ricart, Gemma Frühbeck Title: Moléculas útiles para el tratamiento y/o prevención de trastornos metabólicos asociados a obesidad y resistencia a insulina Patent number: ES2654.7 Assignee: CIBERobn, IDIBGI, Clínica Universidad de Navarra, Barcelona Supercomputing Center.
50
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
51
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
Our research is aimed at identifying newer markers for early detection of metabolic abnormalities as a result of prenatal programming. We are studying current strategies based on epigenetic markers that may help design novel strategies to prevent MS early in life.
52
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
Pediatric Endocrinology Group members Group Leader: Abel López Bermejo
Post-doctorate researchers
Medical researchers
— Judit Bassols — Anna Prats
— Eva Bargalló
Post-graduate researchers — Alexandra Bonmatí — Gemma Carreras — Montserrat Gipsert-Saüch — Inés Osiniri — Pilar Soriano
Collaborators — Cristina Casas — Lourdes Ibáñez — Lluís Mayol — Patrícia Reyner — Montserrat Ros — Joan Carles Vilanova — Francis de Zegher
Technicians — Estíbaliz Platero
Nursing staff — Ferran Díaz
Main line of research · Prevention of obesity and cardiovascular risk in infancy · Molecular bases of infantile obesity. · Cardiovascular risk markers in infancy
53
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
METABOLISM AREA
Publications
Systematic Review”. Dementia and Geriatric Cognitive Disorders. 2013; 36:363-375. PMID: 24022505. I.F.: 2,81.
Originals (I.F.: 31,90): 1. Prats-Puig A, Ortega FJ, Mercader JM, Moreno-Navarrete JM, Moreno M, Bonet N, Ricart W, López-Bermejo A, Fernández-Real JM. “Changes in circulating microRNAs are associated with childhood obesity”. Journal of Clinical Endocrinology and Metabolism. 2013; 98:E1655-60. PMID: 23928666. I.F.: 6,31. 2. Bassols J, Megia A, Soriano-Rodríguez P, Díaz M, PratsPuig A, Gifre M, Simón-Muela I, Torrent S, Borrell AC, Riera-Socasau JC, Vendrell J, de Zegher F, Ibáñez L, LópezBermejo A. “A common gene variant in STK11 is associated with metabolic risk markers and diabetes during gestation”. Fertility and Sterility. 2013; 100:788-92. PMID: 23706335. I.F.: 4,30. 3. Ibáñez L, Díaz M, Sebastiani G, Marcos MV, López-Bermejo A, de Zegher F. “Oral contraception vs insulin sensitization for 18 months in nonobese adolescents with androgen excess: posttreatment differences in C-reactive protein, intima-media thickness, visceral adiposity, insulin sensitivity, and menstrual regularity”. Journal of Clinical Endocrinology and Metabolism. 2013; 98:E902-7. PMID: 23547047. I.F.: 6,31. 4. de Zegher F, Sebastiani G, Diaz M, Gómez-Roig MD, López-Bermejo A, Ibáñez L. “Breast-feeding vs formulafeeding for infants born small-for-gestational-age: divergent effects on fat mass and on circulating IGF-I and highmolecular-weight adiponectin in late infancy”. Journal of Clinical Endocrinology and Metabolism. 2013; 98:1242-7. PMID: 23365126. I.F.: 6,31. 5. Prats-Puig A, Grau-Cabrera P, Riera-Pérez E, CortésMarina R, Fortea E, Soriano-Rodríguez P, de Zegher F, Ibánez L, Bassols J, López-Bermejo A. “Variations in the obesity genes FTO, TMEM18 and NRXN3 influence the vulnerability of children to weight gain induced by short sleep duration”. International Journal of Obesity (Lond). 2013; 37:182-7 PMID: 22391885. I.F.: 5,39. 6. Díaz M, Bassols J, Aragonés G, Mazarico E, López-Bermejo A, Ibáñez L. “Decreased placental expression of preadipocyte factor-1 in children born small-for-gestational-age: association to early postnatal weight gain”. Placenta. 2013; 34:331-4. PMID: 23410724. I.F.: 3,29.
Grants for Research in Progress: - Nuevos determinantes moleculares de la resistencia a la insulina en la edad pediátrica. PI10/00553 Sponsored by: Instituto de Salud Carlos III Duration: 2011 - 2013 Abel López Bermejo - Efectos endocrino-metabólicos, sobre la adiposidad visceral y parámetros de riesgo cardiovascular de la administración de metformina en niños prepuberales con obesidad y marcadores de riesgo para el síndrome metabólico. EC10/252 Sponsored by: Ministerio de Sanidad y Política Social Duration: 2011 - 2013 Abel López Bermejo - Plasticidad del desarrollo de obesidad abdominal y riesgo cardiovascular en la infancia. Sponsored by: Nutribén. Duration: 2012 - 2015 Abel López Bermejo - MoSHCA - My Mobile and Smart Health Care Assistant. ITEA 2 -ip11027 Sponsored by: Ministerio Economia y Competitividad Duration: 2012 - 2015 Abel López Bermejo - Marcas epigenéticas del desarrollo prenatal: Asociación con parámetros de riesgo cardiometabólico en pediatría. (PI13/01257) Sponsored by: Instituto de Salud Carlos III Duration: 2014 - 2016 Abel López Bermejo - Els microRNAs com a nous biomarcadors del creixement pre i postnatal. Sponsored by: Agrupació de Ciències Mèdiques de Girona Duration: 2014 Abel López Bermejo
Review (I.F.: 2,81): 1. Carrion C, Aymerich M, Baillés E, López-Bermejo A. “Cognitive Psychosocial Intervention in Dementia: A
54
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
55
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Neuroscience Area AGING, DISABILITY AND HEALTH CEREBROVASCULAR PATHOLOGY MEDICAL IMAGING NEURODEGENERATION AND NEUROINFLAMMATION
56
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
57
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
Normal and pathological aging. Dementia and Alzheimer's / Neuropsychology / Psychopathology of aging and dementia. Adaptation and validation of psychometric instruments in the field of aging, disability and mental health. Epidemiology of aging: frailty, disability and dependence.
58
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
Aging, Disability and Health Group members Group Leader: Josep Garre-Olmo
Post-graduate researchers
Collaborators — Marta Hernández — Dagmar Keller — Manoli Lonzano
— Oriol Turró
Post-doctorate researchers
Medical researchers
— Laia Calvó
— Josep Lluís Conde — Manuel de Gracia — Jordi Llinàs — Secundí López-Pousa — Joan Vilalta-Franch
Publications Originals (I.F.: 35,44): 1. Conde-Sala JL, Garre-Olmo J, Vilalta-Franch J, Llinàs-Reglà J, Turró-Garriga O, Lozano-Gallego M, Hernández-Ferràndiz M, Pericot-Nierga I, López-Pousa S. “Cognitive decline in Alzheimer’s disease. A follow three or more years of a sample of patients”. Revista de Neurología. 2013;56:593-600. PMID: 23744245. I.F.: 0,93. 2. Carreras-Valls R, Valverde-Lozano J, Benito-Carreras D, Inglés-Torruella J, Vilardell-Ynaraja M, Garre-Olmo J, Gil-Soto R, Escalé-Roca M. “Prevalence of antibodies to hepatitis A virus in healthcare workers and associated variables”. Gaceta Sanitaria. 2013;27:533-6. PMID: 23669502. I.F.: 1,25. 3. López-Pousa S, Garre-Olmo J, de Gracia M, Ribot J, Calvó-Perxas L, Vilalta-Franch J. “Development of a multidimensional measure of fibromyalgia symptomatology: the comprehensive rating scale for fibromyalgia symptomatology”. Journal of Psychosomatic Research. 2013;74:384-92. PMID: 23597325. I.F.: 2,84. 4. Vilalta-Franch J, López-Pousa S, Calvó-Perxas L, GarreOlmo J. “Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality”. American Journal of Geriatric Psychiatry. 2013;21:1135-43. PMID: 23567368. I.F.: 3,52. 5. Conde-Sala JL, Reñé-Ramírez R, Turró-Garriga O, GascónBayarri J, Juncadella-Puig M, Moreno-Cordón L, Viñas-Diez
59
Nursing staff — Mª Angeles Lacarra — Ivana Trastámara
V, Vilalta-Franch J, Garre-Olmo J. “Factors associated with the variability in caregiver assessments of the capacities of patients with Alzheimer disease”. Journal of Geriatric Psychiatry and Neurology. 2013;26:86-94. PMID: 23514974. I.F.: 1,63. 6. Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J, Diez-Espino J, Mundet-Tuduri X, Barrot-De la Puente J, Collde Tuero G; RedGDPS Study Group. “Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study”. BMC Nephrology. 2013;14:46. PMID: 23433046. I.F.: 1,52. 7. Llinàs-Reglà J, Vilalta-Franch J, López-Pousa S, CalvóPerxas L, Garre-Olmo J. “Demographically adjusted norms for Catalan older adults on the Stroop Color and Word Test”. Archives of Clinical Neuropsychology. 2013;28:282-96. PMID: 23380811. I.F.: 1,92. 8. López-Pousa S, Arranz FJ. “Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice”. Patient Preference and Adherence. 2013;7:47-54. PMID: 23341737. I.F.: 1,33. 9. Calvó-Perxas L, López-Pousa S, Turró-Garriga O, de Eugenio R, Linares M, Fernández Mdel M, Castellanos M, Casas I, Turón-Estrada A, Casadevall T, Coromina J, VilaltaFranch J, Garre-Olmo J; Behalf Of The Registry Of Dementias Of Girona Study Group Redegi Study Group. “Pain treatment and its cost in old people with dementia: a descriptive analysis from the Registry of Dementias of Girona (ReDeGi)”. International Journal of Neurosciences. 2013;123:339-46. PMID: 23270366. I.F.: 1,53.
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
10. Becerra Fontal JA, Bagó Granell J, Garré Olmo J, Roig Busquets R, Peris Prats F, Villanueva Leal C. “Evaluation of health-related quality of life in patients candidate for spine and other musculoskeletal surgery”. European Spine Journal. 2013;22:1002-9. PMID: 23263224. I.F.: 2,47. 11. Conde-Sala JL, Reñé-Ramírez R, Turró-Garriga O, GascónBayarri J, Juncadella-Puig M, Moreno-Cordón L, ViñasDiez V, Garre-Olmo J. “Clinical differences in patients with Alzheimer’s disease according to the presence or absence of anosognosia: implications for perceived quality of life”. Journal of Alzheimers Disease. 2013;33:1105-16. PMID: 23128559. I.F.: 3,61. 12. Vilalta-Franch J, Calvó-Perxas L, Garre-Olmo J, TurróGarriga O, López-Pousa S. “Apathy syndrome in Alzheimer’s disease epidemiology: prevalence, incidence, persistence, and risk and mortality factors”. Journal of Alzheimers Disease. 2013;33:535-43. PMID: 23001707. I.F.: 3,61. 13. Vilalta-Franch J, López-Pousa S, Llinàs-Reglà J, CalvóPerxas L, Merino-Aguado J, Garre-Olmo J. “Depression subtypes and 5-year risk of dementia and Alzheimer disease in patients aged 70 years”. International Journal of Geriatric Psychiatry. 2013;28:341-50. PMID: 22588687. I.F.: 3,09.
Grants for Research in Progress: - Projecte AD-retina. Estudi de les troballes fundoscòpiques i tomogràfiques a la retina de pacients amb malaltia d’Alzheimer. Sponsored by: Instituto de Salud Carlos III. Fondo de Investigación Sanitaria Duration: 2012 - 2014 Miguel Ángel Zapata Victori - Estudi Multidisciplinar sobre la Maduresa i l’Envelliment Satisfactori a Girona (MESGI 50) Sponsored by: Dipsalut Duration: 2013 - 2014 Josep Garre Olmo - Estudi multicèntric d’adaptació i validació de la frontotemporal dementia rating scale Sponsored by: Agrupació Ciències Mèdiques de Girona Duration: 2013 - 2014 Oriol Turró Garriga
14. Turró-Garriga O, Garre-Olmo J, Vilalta-Franch J, CondeSala JL, de Gracia Blanco M, López-Pousa S. “Burden associated with the presence of anosognosia in Alzheimer’s disease”. International Journal of Geriatric Psychiatry. 2013;28:291-7. PMID: 22555993. I.F.: 3,09. 15. Garre-Olmo J, Calvó-Perxas L, López-Pousa S, de Gracia Blanco M, Vilalta-Franch J. “Prevalence of frailty phenotypes and risk of mortality in a community-dwelling elderly cohort”. Age and Ageing. 2013;42:46-51. PMID: 22454134. I.F.: 3,11. Reviews (I.F.: 2,70): 1. Avila-Castells P, Garre-Olmo J, Calvó-Perxas L, TurróGarriga O, Alsina E, Carmona O, Perkal H, Roig AM, Cuy JM, Lozano M, Molins A, Vallmajó N, López-Pousa S; Registry Dementia of Girona Study Group. “Drug use in patients with dementia: a register-based study in the health region of Girona (Catalonia/Spain)”. European Journal of Clinical Pharmacology. 2013;69:1047-56. PMID: 23179177. I.F.:2.70
60
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
61
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
Study of biomarkers predicting progress of ischemic lesions. Prediction of clinical evaluation in patients with cerebral hemorrhage through the study of image markers based on magnetic resonance imaging tractography.
62
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
CEREBROVASCULAR PATHOLOGY Group members
Post-graduate researchers
Nursing staff
Group Leader: María del Mar Castellanos
— Carme Gubern — Mikel Terceño — Cecile Van Eendenburg
— Martha Kazimierczak
Post-doctorate researchers — Gemma Huguet — Elisabet Kádár — Juan Manuel Sánchez
Medical researchers — Joaquín Serena — Yolanda Silva
Strategic objectives - Evaluate whether alterations in the anisotropy indexes and MRI tractography of the corticospinal tract and arcuate fasciculus predict the neurological progress of patients with acute, subacute and chronic intracerebral hemorrhage. - Study and compare the tractography affectation patterns of patients with cerebral hemorrhage depending on the location of the hematoma (lobar or deep). - Establish tractography patterns for good short and long term functional prognosis in cerebral hemorrhage. - Use brain MRI to study the incidence of contrast extravasation in patients with spontaneous cerebral hemorrhage of < 12 hours of progress, as well as classify these findings according to the location of the contrast extravasation in the hematoma. - Determine whether the presence of contrast extravasation, or any of the patterns defined, is a predictive marker for relevant growth of the hematoma at 72 hours. - Determine whether the presence of contrast extravasation, or any of the patterns defined, is a predictive marker of mortality or early neurological deterioration of patients. - Determine whether the presence of these contrast extravasation patterns in MRI are related to higher serum concentrations of inflammatory markers (IL-6, TNF-a) and/or markers of blood-brain barrier damage (MMP-9, c-FN, s100 b).
Prevention studies - Study the hemodynamic behaviour (flow volume, cerebral hemodynamic reserve and behaviour of the collateral circulation) of the cerebral circulation in conditions prior to surgical operation and during the ischemia induced
63
by carotid clamping in patients with symptomatic carotid stenosis. - Evaluate the indications of shunt placement as a method for the prevention of ischemia due to carotid clamping. - Identify the predictive hemodynamic patterns of patients at risk of presenting a new intra-operatory or immediate postoperatory neurological event. - Correlation between molecular markers analysed in anatomical parts of symptomatic atheroma plaque (endarterectomy) and molecular markers in peripheral blood. - Screening of markers involved in atherogenesis and vulnerable plaque (to be determined): · Adhesion molecules: P-selectin, ICAM-1, VCAM · Endothelin (ET-1) · Asymmetric dimethylarginine (ADMA)
Main lines of research Study of biomarkers predicting progress of ischemic lesions. Prediction of clinical evaluation in patients with cerebral hemorrhage through the study of image markers based on magnetic resonance imaging tractography. Prediction of the growth of cerebral hematoma by assessing the contrast extravasation in the brain MRI. Relationship between the flow rate in the middle cerebral artery and the invasive measurement of the pressure in the internal carotid artery during carotid endarterectomy: identification of patients at risk. Identification of vulnerable plaque through vulnerable blood.
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
Publications
Diseases. 2013; 22:1326-31. PMID: 23352679. I.F.: 1,99.
Originals (I.F.: 55,92):
8. Purroy F, Jiménez Caballero PE, Gorospe A, Torres MJ, Alvarez-Sabin J, Santamarina E, Martínez-Sánchez P, Cánovas D, Freijo MJ, Egido JA, Ramírez-Moreno JM, AlonsoArias A, Rodríguez-Campello A, Casado I, Delgado-Mederos R, Martí-Fàbregas J, Fuentes B, Silva Y, Quesada H, Cardona P, Morales A, de la Ossa NP, García-Pastor A, Arenillas JF, Segura T, Jiménez C, Masjuán J; Stroke Project of the Spanish Cerebrovascular Diseases Study Group. “Recurrent transient ischaemic attack and early risk of stroke: data from the PROMAPA study”. Journal of Neurology Neurosurgery and Psychiatry 2013; 84:596-603. PMID: 23345284. I.F.: 5,58.
1. Alonso M, Castellanos M, Sanchez JM. “Evaluation of matrix effects in the analysis of volatile organic compounds in whole blood with solid-phase microextraction”. Journal of Separation Science. 2013; 36:3776-82. PMID: 24115582. I.F.:2,59. 2. Gubern C, Camós S, Ballesteros I, Rodríguez R, Romera VG, Cañadas R, Lizasoain I, Moro MA, Serena J, Mallolas J, Castellanos M. “miRNA expression is modulated over time after focal ischaemia: up-regulation of miR-347 promotes neuronal apoptosis”. FEBS Journal. 2013; 280:6233-46. PMID: 24112606. I.F.: 3,99. 3. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, Di Angelantonio E, Di Tullio MR, Lutz JS, Elkind MS, Griffith J, Jaigobin C, Mattle HP, Michel P, Mono ML, Nedeltchev K, Papetti F, Thaler DE. “An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke”. Neurology. 2013; 81:619-25. PMID: 23864310. I.F.: 8,30. 4. Puig J, Blasco G, Daunis-I-Estadella J, Thomalla G, Castellanos M, Figueras J, Remollo S, van Eendenburg C, Sánchez-González J, Serena J, Pedraza S. “Decreased corticospinal tract fractional anisotropy predicts long-term motor outcome after stroke”. Stroke 2013; 44:2016-8. PMID: 23652266. I.F.: 6,02. 5. Puig J, Blasco G, Daunis-I-Estadella J, Thomalla G, Castellanos M, Soria G, Prats-Galino A, Sánchez-González J, Boada I, Serena J, Pedraza S. “Increased corticospinal tract fractional anisotropy can discriminate stroke onset within the first 4.5 hours”. Stroke. 2013; 44:1162-5. PMID: 23463753. I.F.: 6,02. 6. Huynh TJ, Demchuk AM, Dowlatshahi D, Gladstone DJ, Krischek O, Kiss A, Hill MD, Molina CA, Rodriguez-Luna D, Dzialowski I, Silva Y, Czlonkowska A, Lum C,Boulanger JM, Gubitz G, Bhatia R, Padma V, Roy J, Kase CS, Aviv RI; PREDICT/Sunnybrook ICH CTA Study Group. “Spot sign number is the most important spot sign characteristic for predicting hematoma expansion using first-pass computed tomography angiography: analysis from the PREDICT study”. Stroke. 2013; 44:972-7. PMID: 23444309. I.F.: 6,02. 7. Dorado L, Castaño C, Millán M, Aleu A, de la Ossa NP, Gomis M, López-Cancio E, Vivas E, Rodriguez-Campello A, Castellanos M, Dávalos A. “Hemorrhagic risk of emergent endovascular treatment plus stenting in patients with acute ischemic stroke”. Journal of Stroke & Cerebrovascular
9. Thaler DE, Ruthazer R, Di Angelantonio E, Di Tullio MR, Donovan JS, Elkind MS, Griffith J, Homma S, Jaigobin C, Mas JL, Mattle HP, Michel P, Mono ML, Nedeltchev K, Papetti F, Serena J, Weimar C, Kent DM. “Neuroimaging findings in cryptogenic stroke patients with and without patent foramen ovale”. Stroke. 2013; 44:675-80. PMID: 23339957. I.F.: 6,02. 10. Calvó-Perxas L, López-Pousa S, Turró-Garriga O, de Eugenio R, Linares M, Fernández Mdel M, Castellanos M, Casas I, Turón-Estrada A, Casadevall T, Coromina J, VilaltaFranch J, Garre-Olmo J; Behalf Of The Registry Of Dementias Of Girona Study Group Redegi Study Group. “Pain treatment and its cost in old people with dementia: a descriptive analysis from the Registry of Dementias of Girona (ReDeGi)”. International Journal of Neuroscience. 2013;123:339-46. PMID: 23270366. I.F.: 1,53. 11. Thaler DE, Di Angelantonio E, Di Tullio MR, Donovan JS, Griffith J, Homma S, Jaigobin C, Mas JL, Mattle HP, Michel P, Mono ML, Nedeltchev K, Papetti F, Ruthazer R, Serena J, Weimar C, Elkind MS, Kent DM. “The Risk of Paradoxical Embolism (RoPE) Study: initial description of the completed database”. International Journal of Stroke. 2013;8:612-9. PMID: 22883936. I.F.: 4,03. 12. Matías-Gui JA, García-Ramos R, Castellanos M, MartínezVila E, Matias-Guiu J. “What happens to medical articles submitted in Spanish that are not accepted for publication?”. Neurologia. 2013;28:205-11. PMID: 22795919. I.F.: 1,35. 13. Rodríguez-Yáñez M, Castellanos M, Sobrino T, Brea D, Ramos-Cabrer P, Pedraza S, Castiñeiras JA, Serena J, Dávalos A, Castillo J, Blanco M. “Interleukin-10 facilitates the selection of patients for systemic thrombolysis”. BMC Neurology. 2013;13:62. PMID: 23773291. I.F.: 2,49. Reviews (I.F.: 10,74): 1. Østergaard L, Jespersen SN, Mouridsen K, Mikkelsen
64
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
IK, Jonsdottír KÝ, Tietze A, Blicher JU, Aamand R, Hjort N, Iversen NK, Cai C, Hougaard KD, Simonsen CZ, Von WeitzelMudersbach P, Modrau B, Nagenthiraja K, Riisgaard Ribe L, Hansen MB, Bekke SL, Dahlman MG, Puig J, Pedraza S, Serena J, Cho TH, Siemonsen S, Thomalla G, Fiehler J, Nighoghossian N, Andersen G. “The role of the cerebral capillaries in acute ischemic stroke: the extended penumbra model”. Journal of Cerebral Blood Flow and Metabolism. 2013; 33:635-48. PMID: 23443173. I.F.:5.34. 2. Serena J, Irimia P, Calleja S, Blanco M, Vivancos J, AyoMartín O; en representación de la Sociedad Española de Neurosonología (SONES). “Cuantificación ultranosográfica de la estenosis carotídea: recomendaciones de la Sociedad Española de Neurosonología (SONES)” Neurologia 2013;28:435-42. PMID: 23040716. I.F.: 1,35. 3. Rodríguez-Yáñez M, Castellanos M, Freijo MM, López Fernández JC, Martí-Fàbregas J, Nombela F, Simal P, Castillo J; Comitéad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la SEN, Díez-Tejedor E, Fuentes B, Alonso de Leciñana M, Alvarez-Sabin J, Arenillas J, Calleja S, Casado I, Dávalos A, Díaz-Otero F, Egido JA, Gállego J, García Pastor A, Gil-Núñez A, Gilo F, Irimia P, Lago A, Maestre J, Masjuan J, Martínez-Sánchez P, Martínez-Vila E, Molina C, Morales A, Purroy F, Ribó M, Roquer J, Rubio F, Segura T, Serena J, Tejada J, Vivancos J. “Clinical practice guidelines in intracerebral haemorrhage”. Neurologia. 2013;28:236-49. PMID: 21570742. I.F.: 1,35. 4. Avila-Castells P, Garre-Olmo J, Calvó-Perxas L, TurróGarriga O, Alsina E, Carmona O, Perkal H, Roig AM, Cuy JM, Lozano M, Molins A, Vallmajó N, López-Pousa S; Registry Dementia of Girona Study Group. “Drug use in patients with dementia: a register-based study in the health region of Girona (Catalonia/Spain)”. European Journal of Clinical Pharmacology. 2013;69:1047-56. PMID: 23179177. I.F.: 2,70 Multicentric (I.F.: 57,82): 1. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; INTERACT2 Investigators. “Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage”. New England Journal of Medicine. 2013;368:2355-65. PubMed PMID: 23713578. I.F.: 54,42.
prevention of small subcortical strokes trial”. American Journal of Hypertension. 2013;26:1114-22. PMID: 23736109. I.F.: 3,40.
Grants for research in progress: - Estudio de alteración de la permeabilidad de la barrera hematoencefálica y relación con los mecanismos moleculares predictivos de transformación hemorrágica en isquemia cerebral tratada con rt-PA (PI10/01309) Sponsored by: Instituto de Salud Carlos III Duration: 2010 - 2013 Mar Castellanos - Red De Enfermedades Vasculares Cerebrales (ICTUS): RED INVICTUS (RD12/0014/0010) Sponsored by: Instituto de Salud Carlos III Duration: 2013 - 2015 Mar Castellanos - WAKEUP. Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebocontrolled trial. Sponsored by: European Union. 7th Framework Programme. Duration: 2011 - 2016 Chistian Gerlof – Salvador Pedraza - Validación de nuevos parámetros de Difusión tensor como biomarcadores de imagen en el infarto cerebral. Estudio anatómico de Tracto Corticoespinal (PI09/0596) Sponsored by: Instituto de Salud Carlos III Duration: 2010 - 2013 Salvador Pedraza - Transformación hemorrágica en isquemia cerebral tras administracion de RT-PA: Participación de biomarcadores endoteliales y endotelio-protección mediante administracion de peptidos (PI13/02258) Sponsored by: Instituto de Salud Carlos III Duration: 2014 - 2016 Mar Castellanos
2. White CL, Pergola PE, Szychowski JM, Talbert R, CervantesArriaga A, Clark HD, Del Brutto OH, Godoy IE, Hill MD, Pelegrí A, Sussman CR, Taylor AA, Valdivia J, Anderson DC, Conwit R, Benavente OR; SPS3 Investigators. “Blood pressure after recent stroke: baseline findings from the secondary
65
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
The research of the group has been focused on the validation and qualification of Imaging Biomarkers on Medicine. We have published relevant papers mainly on Stroke and Brain tumors imaging. The group is international leader in the research about the utility of Diffusion Tensor Imaging (DTI) in the management of stroke patients to predict the clinical outcome.
66
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
MEDICAL IMAGING Group members
Group Leader: Salvador Pedraza
Post-doctorate researchers — Elda Balliu — Brigite Beltran — Gerard Blasco — Jorge Guibernau — Elsa Pérez — Josep Puig — Laia Valls
Medical researchers
Technicians
— Arantxa Gelabert — Eva Gómez — Gemma Laguillo — Albert Maroto
— Joan Banyos
Collaborators
Nursing staff — Javier Molina
— Joan Banyos — Josep Daunis — Francisco Reina
Strategic objectives
Prevention studies
Our global strategic goal is the validation of the imaging biomarkers in specific diseases (stroke, brain tumours, and metabolic syndrome).
Validation of the usefulness of Diffusion Tensor in the management and prognosis of stroke patients. Validation of the usefulness of Diffusion Tensor in the assessment of the evolution time of stroke. Validation of the usefulness of the Diffusion/FLAIR mismatch in the treatment of patients with wake-up stroke. Validation of perfusion CT in the diagnosis of stroke. Usefulness of the study of arterial wall elasticity in the prediction of cardiovascular risk. Usefulness of intravascular contrast in defining the real extension of aggressive brain tumors. Usefulness of the Diffusion Tensor in the assessment of lumbar disc degeneration. Validation of echographic biomarkers (mean intimamedia index degree d; hepatic steatosis) on estimating the metabolic syndrome in obese patients. Usefulness of Diffusion Tensor in the management of patients with hydrocephaly.
67
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
Publications
acute ischemic stroke”. Stroke. 2013;44:e33. PMID: 23412373. I.F.: 6,02.
Originals (I.F.: 40,45): 1. Soria G, Tudela R, Márquez-Martín A, Camón L, Batalle D, Muñoz-Moreno E, Eixarch E, Puig J, Pedraza S, Vila E, PratsGalino A, Planas AM. “The ins and outs of the BCCAo model for chronic hypoperfusion: a multimodal and longitudinal MRI approach”. PLoS One. 2013;8:e74631. PMID: 24058609. I.F.: 3,53. 2. Wintermark M, Albers GW, Broderick JP, Demchuk AM, Fiebach JB, Fiehler J, Grotta JC, Houser G, Jovin TG, Lees KR, Lev MH, Liebeskind DS, Luby M, Muir KW, Parsons MW, von Kummer R, Wardlaw JM, Wu O, Yoo AJ, Alexandrov AV, Alger JR, Aviv RI, Bammer R, Baron JC, Calamante F, Campbell BC, Carpenter TC, Christensen S, Copen WA, Derdeyn CP, Haley EC Jr, Khatri P, Kudo K, Lansberg MG, Latour LL, Lee TY, Leigh R, Lin W, Lyden P, Mair G, Menon BK, Michel P, Mikulik R, Nogueira RG, Ostergaard L, Pedraza S, Riedel CH, Rowley HA, Sanelli PC, Sasaki M, Saver JL, Schaefer PW, Schellinger PD, Tsivgoulis G, Wechsler LR, White PM, Zaharchuk G, Zaidat OO, Davis SM, Donnan GA, Furlan AJ, Hacke W, Kang DW, Kidwell C, Thijs VN, Thomalla G, Warach SJ; Stroke Imaging Research (STIR) and Virtual International Stroke Trials Archive (VISTA)-Imaging Investigators. “Acute Stroke Imaging Research Roadmap II”. Stroke. 2013;44:2628-39. PMID: 23860298. I.F.: 6,02. 3. Hermitte L, Cho TH, Ozenne B, Nighoghossian N, Mikkelsen IK, Ribe L, Baron JC, Østergaard L, Derex L, Hjort N, Fiehler J, Pedraza S, Hermier M, Maucort-Boulch D, Berthezène Y. “Very low cerebral blood volume predicts parenchymal hematoma in acute ischemic stroke”. Stroke. 2013;44:2318-20. PMID: 23723309. I.F.: 6,02. 4. Puig J, Blasco G, Daunis-I-Estadella J, Thomalla G, Castellanos M, Figueras J, Remollo S, van Eendenburg C, Sánchez-González J, Serena J, Pedraza S. “Decreased corticospinal tract fractional anisotropy predicts long-term motor outcome after stroke”. Stroke. 2013;44:2016-8. PMID: 23652266. I.F.: 6,02.
7. Puig J, Blasco G, Essig M, Daunis-I-Estadella J, Laguillo G, Quiles AM, Remollo S, Bergmann K, Joly C, Bernado L, Sánchez-González J, Pedraza S. “Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma”. European Radiology. 2013;23:1093-101. PMID: 23085863. I.F.: 4,34. 8. Rodríguez-Yáñez M, Castellanos M, Sobrino T, Brea D, Ramos-Cabrer P, Pedraza S, Castiñeiras JA, Serena J, Dávalos A, Castillo J, Blanco M. “Interleukin-10 facilitates the selection of patients for systemic thrombolysis”. BMC Neurology. 2013;13:62. PMID: 23773291. I.F.: 2,49. 9. Parody Rúa E, Pedraza Gutiérrez S, Caminal Homar J, García Gil MM, Serena Leal J, Dávalos Errando A.” Influencia del diagnóstico precoz con resonancia magnética del infarto cerebral agudo en la función global de salud y en los costes de la atención del paciente”. Gestión y Evaluación de Costes Sanitarios 2013; 14:409-18. Case Report (I.F.: 0,83): 1. Quiles AM, Laguillo G, Gómez E, Remollo S, Pedraza S. “Compresión medular por metástasis de hepatocarcinoma en paciente infectado por el virus de la inmunodeficiencia humana. A propósito de un caso”. Gastroenterología y Hepatología. 2013;36:437-8. PMID: 23465581. I.F.: 0,83. Editorial (I.F.: 1,24): 1. Pedraza S. “Utilidad de la resonancia magnética en el traumatismo craneoencefálico”. Medicina Intensiva. 2013; 37(6):373-4. PMID: 23578481. I.F.: 1,24. Reviews (I.F.: 5,34):
5. Puig J, Blasco G, Daunis-I-Estadella J, Thomalla G, Castellanos M, Soria G, Prats-Galino A, Sánchez-González J, Boada I, Serena J, Pedraza S. “Increased corticospinal tract fractional anisotropy can discriminate stroke onset within the first 4.5 hours”. Stroke. 2013;44:1162-5. PMID: 23463753. I.F.: 6,02. 6. Pedraza S, Puig J, Blasco G. Letter by Pedraza et al regarding article, “Density of thrombus on admission CT predicts revascularization efficacy in large vessel occlusion
1. Østergaard L, Jespersen SN, Mouridsen K, Mikkelsen IK, Jonsdottír KÝ, Tietze A, Blicher JU, Aamand R, Hjort N, Iversen NK, Cai C, Hougaard KD, Simonsen CZ, Von WeitzelMudersbach P, Modrau B, Nagenthiraja K, Riisgaard Ribe L, Hansen MB, Bekke SL, Dahlman MG, Puig J, Pedraza S, Serena J, Cho TH, Siemonsen S, Thomalla G, Fiehler J, Nighoghossian N, Andersen G. “The role of the cerebral capillaries in acute ischemic stroke: the extended penumbra model”. Journal Cerebral Blood Flow and Metabolism. 2013;33:635-48. PMID: 23443173. I.F.: 5,34. 2. Juanpere S, Cañete N, Ortuño P, Martínez S, Sanchez G, Bernado L. “A diagnostic approach to the mediastinal
68
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
masses”. Insights into Imaging. 2013;4:29-52. PMID: 23225215. Books: - Casas JD, Vilanova JC, Pedraza S, Muñoz C, Maroto A, Guirao S, Fuentes R, Barceló J, Balliu E. “Guía práctica del tutor en el aprendizaje basado en problemas. Preguntas y algunas respuestas”. Actividades de innovación en la educación universitaria española (APURF). Capitulo 4. Pag 33.ISBN: 978-1-291-38912-8.
Grants for Research in Progress: - Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial (HEALTH-F2-2011- 278276) Grant: European Comission Duration: 2011-2016 Salvador Pedraza - EPI_CT. Estudi de cohort de nens amb exposició diagnóstica substancial a radiacions ionitzants. Grant: European Comission Duration: 2012-2015 Salvador Pedraza - Developing computer radiological game as a tool for problem based-learning (PBL) of radiology for undergraduate medical education (MEDGAME) Grant: Radiological Society of North America Duration: 2012-2013 Salvador Pedraza - Desarrollo de un biomarcador radiologico basado en el analisis de la conectividad estructural y funcional en pacientes con infarto cerebral agudo para la prediccion de la recuperacion funcional (PI13/02545) Grant: Instituto de Salud Carlos III Duration: 2014-2016 Salvador Pedraza
69
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
Multiple Sclerosis (MS) currently lacks a clear prognosis as to the clinical evolution on diagnosis. Our multidisciplinary research group consisting aims to respond to the different challenges presented by MS, broaden our knowledge of the disease, and to transfer this knowledge to the society.
70
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
NEURODEGENERATION AND NEUROINFLAMATION Team involved in “Red Española de Esclerosis Múltiple (REEM)”
Group members
Group Leader: Lluís Ramió
Post-doctorate researchers
Medical researchers
Technicians
— Jordi Gich — Ester Quintana
— David Genís — Fabian Márquez — Ana Quiles — Lluís Ramió — René Robles
— Judith Oriol — Neus Pueyo
Post-graduate researchers — Rebeca Menéndez
Collaborators — Brigitte Beltrán — Laura Fábregas — Pepi López — Hector Perkal
Nursing staff — Judit Guerrero — Miguel Merchan — Miguel Ángel Robles
Strategic objectives - Be the reference group in the province of Girona for research and education in multiple sclerosis and other neurodegenerative diseases. - Have a national and international presence in the field of research into multiple sclerosis. - Consolidate clinical research in multiple sclerosis. - Initiate and consolidate basic research into multiple sclerosis. - Promote and lead research into new treatments for multiple sclerosis. - Initiate clinical research into other neurodegenerative diseases (Parkinson’s disease). - Consolidate clinical research into hereditary ataxia. - Establish research collaboration with other national and international groups working on multiple sclerosis. - Promote research into multiple sclerosis in nursing and neuropsychology. - Promote training and education in multiple sclerosis for healthcare professionals, specialists and affected patients and their family.
71
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
Main lines of research
Publications
Priority clinical-healthcare lines: 1. Study of neuropsychological disorders and cognitive rehabilitation in multiple sclerosis. 2. Study of the emotional impact, ability to cope, and adaptation to the diagnosis of multiple sclerosis. 3. Study of fatigue in multiple sclerosis. 4. Improve compliance with immunomodulatory treatment in multiple sclerosis. 5. Application of new brain MRI techniques as prognosis markers in multiple sclerosis. 6. Computer-based organisation of lesions detected by brain MRI in patients with multiple sclerosis.
Originals (I.F.: 14,54):
Priority lines in basic research: 1. Study of the gene expression in demyelinating diseases including multiple sclerosis. 2. Study of the molecular expression in multiple sclerosis as a model of chronic inflammatory disease. 3. Determination of biological prognosis factors in cerebrospinal fluid and serum for the evolution of multiple sclerosis (genetic factors, biochemical factors, environmental factors such as vitamin D, virus and others). 4. Determination of biological response factors (genetic and biochemical) to immunomodulatory treatments in multiple sclerosis. 5. Bank of DNA, CSF and serum samples of neuroimmunological diseases.
1. Sepúlveda M, Blanco Y, Rovira A, Rio J, Mendibe M, Llufriu S, Gabilondo I, Villoslada P, Castilló J, Corral J, Ayuso T, Iñiguez C, Santos S, Guijarro C, Ramió-Torrentà L, Sempere AP, Olascoaga J, Graus F, Montalban X, Saiz A. “Analysis of prognostic factors associated with longitudinally extensive transverse mielitis”. Multiple Sclerosis Journal. 2013;19:742-8. PMID: 23037550. I.F.: 4,86. 2. Arnal-Garcia C, García-Montero MR, Málaga I, MillánPascual J, Oliva-Nacarino P, Ramió-Torrentà L, OrejaGuevara C. “Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis”. European Journal of Paediatric Neurology. 2013;17:50-4. PMID: 23021975. I.F.: 1,93. 3. Fernández V, Valls-Sole J, Relova JL, Raguer N, Miralles F, Dinca L, Taramundi S, Costa-Frossard L, Ferrandiz M, Ramió-Torrentà L, Villoslada P, Saiz A, Calles C, Antigüedad A, Alvarez-Cermeño JC, Prieto JM, Izquierdo G, Montalbán X, Fernández O. “Recommendations for the clinical use of motor evoked potentials in multiple sclerosis”. Neurologia. 2013;28:408-16. PMID: 22995526. I.F.: 1,35. 4. Pérez-Miralles F, Sastre-Garriga J, Tintoré M, Arrambide G, Nos C, Perkal H, Río J, Edo MC, Horga A, Castilló J, Auger C, Huerga E, Rovira A, Montalban X. “Clinical impact of early brain atrophy in clinically isolated síndromes”. Multiple Sclerosis Journal. 2013;19:1878-86. PMID: 23652215 I.F.: 4,86. 5. Calvó-Perxas L, López-Pousa S, Turró-Garriga O, de Eugenio R, Linares M, Fernández Mdel M, Castellanos M, Casas I, Turón-Estrada A, Casadevall T, Coromina J, VilaltaFranch J, Garre-Olmo J; Behalf Of The Registry Of Dementias Of Girona Study Group Redegi Study Group. “Pain treatment and its cost in old people with dementia: a descriptive analysis from the Registry of Dementias of Girona (ReDeGi)”. International Journal of Neuroscience. 2013;123:339-46. PMID: 23270366. I.F.: 1,53. Reviews (I.F.: 6,40): 1. Avila-Castells P, Garre-Olmo J, Calvó-Perxas L, TurróGarriga O, Alsina E, Carmona O, Perkal H, Roig AM, Cuy JM, Lozano M, Molins A, Vallmajó N, López-Pousa S; Registry Dementia of Girona Study Group. “Drug use in patients with dementia: a register-based study in the health region of Girona (Catalonia/Spain)”. European Journal of Clinical Pharmacology. 2013;69:1047-56. PMID: 23179177. I.F.: 2,70. 2. Fernández Ó, Arnal-García C, Arroyo-González R, Brieva
72
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
NEUROSCIENCE AREA
L, Calles-Hernández MC, Casanova-Estruch B, Comabella M, de las Heras V, García-Merino JA, Hernández-Pérez MA, Izquierdo G, Matas E, Meca-Lallana JE, Mendibe-Bilbao Mdel M, Muñoz-García D, Olascoaga J, Oreja-Guevara C, Prieto JM, Ramió-Torrentà L, Rodríguez-Antigüedad A, Saiz A, Téllez N, Villar LM, Tintoré M; Post-ECTRIMS Group. “Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (III)”. Revista de Neurologia. 2013;57:31729. PMID: 24052443. I.F.: 0,93. 3. Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, Comabella M, de Las Heras V, García-Merino JA, Hernández-Pérez MA, Izquierdo G, Matas E, Meca-Lallana JE, Mendibe-Bilbao Mdel M, Muñoz-García D, Olascoaga J, Oreja-Guevara C, Prieto JM, Ramió-Torrentà L, Rodríguez-Antigüedad A, Saiz A, Téllez N, Villar LM, Tintoré M; Grupo Post-ECTRIMS. “Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (II)”. Revista de Neurologia. 2013;57:26981. PMID: 24008938. I.F.: 0,93.
Grants for research in progress: - Identificación de Genes de Susceptibilidad en Esclerosis Múltiple. Análisis Clínico y de Ligamiento Genético en una extensa Familia Gitana (PI10/02649) Grant: Instituto de Salud Carlos III Duration: 2011-2013 Lluís Ramió i Torrenta - Esclerosi múltiple i vitamina D: relació entre els nivells circulants de 25-hidroxi-vitamina D i evolució clínica i radiològica dels pacients amb esclerosi múltiple Grant: Agrupació de Ciències Mèdiques de Girona. Premio Agrupació de Ciències Mèdiques de Girona. Duration: 2012 - 2013 René Robles Cedeño
4. Fernández Ó, Arnal-García C, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, Comabella M, de Las Heras V, García-Merino JA, Hernández-Pérez MA, Izquierdo G, Matas E, Meca-Lallana JE, Mendibe-Bilbao Mdel M, Muñoz-García D, Olascoaga J, Oreja-Guevara C, Prieto JM, Ramió-Torrentà L, Rodríguez-Antigüedad A, Saiz A, Téllez N, Villar LM, Tintoré M; Grupo Post-ECTRIMS. “Review of the novelties presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I)”. Revista de Neurologia. 2013;57:21729. PMID: 23975528. I.F.: 0,93. 5. Fernández Ó, Arroyo-González R, Rodríguez-Antigüedad A, García-Merino JA, Comabella M, Villar LM, Izquierdo G, Tintoré M, Oreja-Guevara C, Álvarez-Cermeño JC, MecaLallana JE, Prieto JM, Ramió-Torrentà L, Martínez-Yélamos S, Montalban X. “Biomarkers in multiple sclerosis”. Revista de Neurologia. 2013;56:375-90. PMID: 23520007. I.F.: 0,93.
73
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Oncology and hematology Area HEPATOBILIARY & PANCREATIC SURGERY AND ONCOLOGY DESCRIPTIVE EPIDEMIOLOGY, GENETICS AND CANCER PREVENTION HEMATOLOGY MOLECULAR ONCOLOGY
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
76
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
HEPATOBILIARY & PANCREATIC SURGERY AND ONCOLOGY Group members
Group Leader: Joan Figueras Felip
Medical researchers — Ernest Castro — Antoni Codina — Esther Diaz — Laia Falgueras — Raquel Guardeño — Xavi Hernández — Santiago López-Ben — Albert Maroto — Rosa Ortiz — Berta Pardina — Pere Planellas — Bernat Queralt — Silvia Torres
Collaborators — Eugeni Casals — Mª José Ferri — Charo Garcia — Hector Daniel González — Carina Jardí — Rosa Peracaula — Pilar Solé — Jordi Soriano
Publications Originals (I.F.: 5,84):
Reviews (I.F.: 39,21):
1. Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, Ortiz R, Ferri MJ, de Bolós C, Figueras J, de Llorens R, Vidal-Vanaclocha F, Peracaula R. “α2,3-sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues”. International Journal of Biochemistry and Cell Biology. 2013;45:1748-57. PMID: 23726834. I.F.: 4,24.
1. Søreide K, Alderson D, Bergenfelz A, Beynon J, Connor S, Deckelbaum DL, Dejong CH, Earnshaw JJ, Kyamanywa P, Perez RO, Sakai Y, Winter DC; International Research Collaboration in Surgery (IRIS) ad-hoc working group. “Strategies to improve clinical research in surgery through international collaboration”. Lancet. 2013;382:1140-51. PMID: 24075054. I.F.: 39,21.
2. Figueras J, Lopez-Ben S, Alsina M, Soriano J, HernandezYagüe X, Albiol M, Guardeño R, Codina-Barreras A, Queralt B. “Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma”. Clinical and Translational Oncology. 2013;15:460-6. PMID: 23143951 I.F.: 1,60.
Grants for research in progress:
77
- Ventajas hemodinámicas y metabólicas del pinzamiento hiliar selectivo en las resecciones hepáticas segmentarias frente al pinzamiento hiliar completo (PI11/01269) Sponsored by: Instituto de Salud Carlos III Duration: 2012 - 2014 Joan Figueras Felip
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
Cancer registries are the key component of a knowledge management system for cancer, contributing to: 路 Scientific research into causes and management 路 An evidence base for policy making 路 The monitoring of policy implementation
78
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
DESCRIPTIVE EPIDEMIOLOGY, GENETICS AND CANCER PREVENTION Group members
Group Leader: Rafael Marcos Gragera
Post-doctorate researchers
Medical researchers
Rafael Fuentes — Bernat Serdà — Neus Vilar
— Carme Carmona — Angel Izquierdo — Jordi Rubió — Loreto Vilardell
Post-graduate researchers
Collaborators — Judit Moreno
Secretary — Joana Fuentes
— Maria Buxó — Gemma Osca — Monserrat Puig
Publications
GRELL study in cut-off variability in the Romance language countries”. Breast. 2013;22:476-81. PMID: 23669022. I.F.: 2,58.
Originals (I.F.: 38,33): 1. Renart G, Saez M, Saurina C, Marcos-Gragera R, Ocaña-Riola R, Martos C, Barceló MA, Arribas F, Alcalá T. “A common error in the ecological regression of cancer incidence on the deprivation index”. Revista Panamericana de Salud Pública. 2013;34:83-91. PMID: 24096972. I.F.: 0,72. 2. Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Lloveras N, Marcos-Gragera R. “Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain”. Haematologica. 2013;98:e95-7. PMID: 23812933. I.F.: 5,87. 3. Crocetti E, Caldarella A, Ferretti S, Ardanaz E, Arveux P, Bara S, Barrios E, Bento MJ, Bordoni A, Buzzoni C, Candela G, Colombani F, Delafosse P, Federico M, Francart J, Giacomin A, Grosclaude P, Guizard AV, Izarzugaza I, Konzelmann I, La Rosa F, Lapotre B, Leone N, Ligier K, Mangone L, MarcosGragera R, Martinez R, Michelena MJ, Michiara M, Miranda A, Molinié F, Mugarza-Gomez C, Paci E, Piffer S, Puig-Vives M, Sacchettini C, Sánchez MJ, Traina A, Tretarre B, Tumino R, Van Vaerenbergh E, Velten M, Woronoff AS. “Consistency and inconsistency in testing biomarkers in breast cancer. A
79
4. Esteban L, Clèries R, Gálvez J, Pareja L, Escribà JM, Sanz X, Izquierdo A, Galcerán J, Ribes J. “REGSTATTOOLS: freeware statistical tools for the analysis of disease population databases used in health and social studies”. BMC Public Health. 2013;13:201. PMID: 23497219. I.F.: 2,32. 5. Gatta G, Rossi S, Foschi R, Trama A, Marcos-Gragera R, Pastore G, Peris-Bonet R, Stiller C, Capocaccia R; EUROCARE Working Group. “Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002”. Haematologica. 2013;98:744-52. PMID: 23403323. I.F.: 5,87. 6. Maynadié M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, Capocaccia R, Giacomin A, Lutz JM, Martos C, Sankila R, Johannesen TB, Simonetti A, Sant M; HAEMACARE Working Group. “Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study”. Haematologica. 2013;98:230-8. PMID: 22983589. I.F.: 5,87. 7. Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, TorrellaRamos A, Martos C, Ardanaz E, Chirlaque MD, Perucha J, Díaz JM, Mateos A, Machón M, Marcos-Gragera R.
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
Grants for research in progress:
“Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study”. Gynecologic Oncology. 2013;130:609-14. PMID: 23747837. I.F.: 3,69.
- Estudio multicaso-control de base poblacional (cáncer de mama y leucemia linfática crónica) (PI11/02213) Sponsored by: Instituto de Salud Carlos III. Fondo de Investigación Sanitaria (FIS) Duration: 01/01/2012 - 31/12/2014 Loreto Vilardell Gil
8. Pérez-García A, Osca G, Bosch-Vizcaya A, Kelleher N, Santos NY, Rodríguez R, González Y, Roncero JM, Coll R, Serrando M, Lloveras N, Tuset E, Gallardo D. “Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription”. Human Immunology. 2013;74:1219-24. PMID: 23756164. I.F.: 2,28.
- Evaluación del efecto del programa de detección precoz del cáncer de mama de la “Regió Sanitaria de Girona” mediante el cruce con Registro Poblacional de cáncer de Girona Sponsored by: Ministerio de Educación. Programa de Formación del Profesorado Universitario (FPU). Duration: 2010 - 2014 Rafael Marcos-Gragera / Marc Saez Beneficiària: Montserrat Puig
9. Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, Capocaccia R; RARECARE WG (MarcosGragera R). “Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project”. Cancer Epidemiology. 2013;37:850-6. PMID: 24050903. I.F.: 2,56
- Epidemiologia de les neoplasies hematològiques Sponsored by: Agaur. Programa de Formació d’investigadors (FI) Duration: 2010 - 2014 Rafael Marcos-Gragera / Marc Saez Beneficiària: Gemma Osca
10. Gatta G; Mallone S; van der Zwan JM; Trama A; Siesling S; Capocaccia R; the EUROCARE Working Group [MarcosGragera R; Izquierdo A; Vilardell L]. “Cancer prevalence estimates in Europe at the beginning of 2000”. Annals of Oncology. 2013; 24:1660-1666. PMID: 23553062. I.F.: 6,58 Multicentric (I.F.: 7.38): 1. Leclère B; Molinié F; Trétarre B; Stracci F; Daubisse-Marliac L; Colonna M & GRELL working group (Montse Puig-Vives; Carla Camprubí-Font & Rafael Marcos-Gragera). “Trends in incidence of breast cancer among women under 40 in seven European countries: a GRELL cooperative study”. Cancer Epidemiology. 2013;37:544-9. PMID: 23768969. I.F.: 2.56. 2. van der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, Dei Tos AP, Baudin E, Poston G, Links T; the RARECARE WG. “Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project”. European Journal of Cancer 2013;49:2565-78. PMID: 23541566. I.F.: 4.82.
- Incidencia, supervivencia y tendencias del cáncer en adolescentes en España: Un estudio cooperativo de 11 registros de càncer (PI10/01617) Sponsored by: Ministerio de Economía y Competitividad. Duration: 2011 - 2013 Investigador responsable: Rafael Peris Bonet Investigador col·laborador: Rafael Marcos-Gragera
Books: 1. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R and Ferlay J eds (2013) . “Cancer Incidence in Five Continents, Vol. X” (electronic version) Lyon, IARC.
80
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
Our group has been investigating the impact of mHAg mismatches on clinical outcome after allogeneic hematopoietic stem cell transplantation from an HLAidentical sibling donor. Currently, we have DNA samples and clinical information from more than 1700 patient/donor pairs ready to analyse the correlation between genotype and clinical outcome.
82
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
HEMATOLOGY Team envolved in “Red Temática de Investigación Cooperativa en Cáncer (RTICC)”
Group members Group Leader: David Gallardo Giralt
Post-graduate researchers — Anna Bosch — Gemma Osca — Nazly Santos
Technicians
Collaborators
— Rocío Rodríguez
— Rosa Coll — Cristalina Fernández — Yolanda González — Ramon Guardia — Nichollas Kelleher — Natàlia Lloveras — Josep Mª Roncero — Esperanza Tuset
Publications
Nieto JB, Martínez C, Pérez A, Montoro J, Garcia-Noblejas A, Solano C; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). “A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation”. American Journal of Hematology. 2013; 88:883-9. PMID: 23813863. I.F.: 3,48.
Originals (I.F.: 62,03): 1. Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Lloveras N, Marcos-Gragera R. “Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain”. Haematologica. 2013;98:e95-7. PMID: 23812933. I.F.: 5,87.
5. Nomdedéu JF, Hoyos M, Carricondo M, Bussaglia E, Estivill C, Esteve J, Tormo M, Duarte R, Salamero O, de Llano MP, García A, Bargay J, Heras I, Martí-Tutusaus JM, Llorente A, Ribera JM, Gallardo D, Aventin A, Brunet S, Sierra J; CETLAM Group. “Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML”. Leukemia. 2013;27:2157-64. PMID: 23584566. I.F.: 9,38.
2. Pérez-García A, Osca G, Bosch-Vizcaya A, Kelleher N, Santos NY, Rodríguez R, González Y, Roncero JM, Coll R, Serrando M, Lloveras N, Tuset E, Gallardo D. “Kinetics of the CTLA-4 isoforms expression after T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription”. Human Immunology. 2013;74:1219-24. PMID: 23756164. I.F.: 2,28. 3. Martín-Antonio B, Suarez-Lledo M, Arroyes M, FernándezAvilés F, Martínez C, Rovira M, Espigado I, Gallardo D, Bosch A, Buño I, Martínez-Laperche C, Jiménez-Velasco A, de la Cámara R, Brunet S, Nieto JB, Urbano-Ispizua A. “A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT”. Bone Marrow Transplantation. 2013;48:1205-11. PMID: 23542224. I.F.: 3,47. 4. Guillem V, Hernández-Boluda JC, Gallardo D, Buño I, Bosch A, Martínez-Laperche C, de la Cámara R, Brunet S, Martin C,
83
6. Fernandez C, Santos-Silva MC, López A, Matarraz S, JaraAcevedo M, Ciudad J, Gutierrez ML, Sánchez ML, SalvadorOsuna C, Berruezo MJ, Díaz-Arias JÁ, Palomo-Hernández AM, Colado E, González N, Gallardo D, Asensio A, GarcíaSánchez R, Saldaña R, Cerveró C, Carboné-Bañeres A, Gutierrez O, Orfao A. “Newly diagnosed adult AML and MPAL patients frequently show clonal residual hematopoiesis”. Leukemia. 2013;27:2149-56. PMID: 23579575. I.F.:9,38. 7. Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, Puig N, Sebastián E, Jiménez C, Mateos MV, Oriol A, Rosiñol L, Palomera L, Teruel AI, González Y, Lahuerta JJ, Bladé J, Gutiérrez NC, Fernández-
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
Redondo E, González M, San Miguel JF, García-Sanz R. “Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple mieloma”. British Journal of Haematology. 2013;163:223-34.PMID: 23952215. I.F.: 4,96. 8. Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F. “Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia”. Blood. 2013;122:3951-9. PMID: 24124086. I.F.: 9,78. 9. Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MP, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J. “Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease”. European Journal of Haematology. 2013;91:209-18. PMID: 23646898. I.F.: 2,41. 10. Pratcorona M, Brunet S, Nomdedéu J, Ribera JM, Tormo M, Duarte R, Escoda L, Guàrdia R, Queipo de Llano MP, Salamero O, Bargay J, Pedro C, Martí JM, Torrebadell M, Díaz-Beyá M, Camós M, Colomer D, Hoyos M, Sierra J, Esteve J. “Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy”. Blood. 2013;121:2734-8. PMID: 23377436. I.F.: 9,78. 11. Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F. “Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors”. Medicina Clinica (Barc). 2013;141:95-9. PMID: 23433665. I.F.: 1,25.
84
Grants for research in progress: - Papel de los polimorfismos genéticos de CD38 y CD31 en la leucemia linfática crónica. Sponsored by: Fundación Mutua Madrileña Duration: 2011 - 2013 Josep Mª Roncero - Biobanco de aloTPH del GETH. Polimorfismos en antígenos menores de histocompatibilidad y genes moduladores de respuesta inmune como predictores de alorreactividad. (PI11/01690) Sponsored by: Instituto de Salud Carlos III Duration: 2012 - 2014 David Gallardo - Minor Histocompatibility antigens as mediators of immune alloreactivity in human transplantation. Sponsored by: Fundació Marató TV3 Duration: 2013 - 2015 David Gallardo - Implicación de los antígenos menores de histocompatibilidad en el éxito del trasplante alogénico de progenitores hematopoyéticos. Sponsored by: Fundación Mutua Madrileña Duration: 2009 - 2013 David Gallardo - Polimorfismos genéticos implicados en la enfermedad del injerto contra el huésped y en la supervivencia tras trasplante alogénico de progenitores hematopoyéticos. Banco nacional de ADN. (PI080413) Sponsored by: Instituto de Salud Carlos III Duration: 2009 - 2013 David Gallardo
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
Bioenergetic metabolism of tumour stem cells. Molecular and pre-clinical basis for the metabolic treatment of cancer. Autophagy and Cancer. Autophagy in tumor stem cells. Autophagy and resistance to cancer treatments.
86
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
MOLECULAR ONCOLOGY Group members Group Leader: Javier Menéndez
Post-Docorate researchers
Post-graduate researchers
— Elisabet Cuyàs — Cristina Oliveras — Alejandro Vázquez
— Bruna Corominas — Sílvia Cufí
Collaborators — Joaquim Bosch — Eugeni López — Begoña Martin
Strategic objectives
Main lines of research
1. Definition of a new intrinsic characteristic (“hallmark”) of cancer: “METABO-STEMNESS” (the bioenergetic metabolism as a causal mechanism of the properties of self-renovation, immortality and pluripotency of tumor stem cells).
Metabolism and cancer Bioenergetic metabolism of tumour stem cells. Molecular and pre-clinical basis for the metabolic treatment of cancer. Autophagy and Cancer. Autophagy in tumor stem cells. Autophagy and resistance to cancer treatments.
2. Treatment of cancer through strategies to reprogram the tumor metabolism: Repositioning of anti-metabolic drugs from other diseases to increase and diversify the arsenal of anti-tumor drugs.
Bioenergetic Metabolism, Autophagy And Aging Biocompounds: Anti-Tumor And Anti-Aging Activity. Repositioning of Anti-Metabolic Drugs for the Metabolic Treatment of Cancer.
87
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
Publications
HER2-positive breast cancer”. Scientific Reports. 2013;3:2469. PMID: 23965851. I.F.: 5,08.
Originals (I.F.: 77,71): 1. Manuel Iglesias J, Beloqui I, Garcia-Garcia F, Leis O, VazquezMartin A, Eguiara A, Cufi S, Pavon A, Menendez JA, Dopazo J, Martin AG. “Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin”. PLoS One. 2013;8:e77281. PMID: 24124614. I.F.: 3,53. 2. Vázquez-Martin A, Cufí S, López-Bonet E, Corominas-Faja B, Cuyàs E, Vellon L, Iglesias JM, Leis O, Martín AG, Menendez JA. “Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells”. Cell Cycle. 2013;12:3471-7. PMID: 24107627. I.F.: 5,01. 3. Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, SeguraCarretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA. “Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin”. Cell Cycle. 2013;12:3390-404. PMID: 24047698. I.F.: 5,01. 4. Vázquez-Martin A, Cufí S, Oliveras-Ferraros C, TorresGarcia VZ, Corominas-Faja B, Cuyàs E, Bonavia R, Visa J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA. “IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations”. Scientific Reports. 2013;3:2560. PMID: 23994953. I.F.: 5,08. 5. Cufí S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, López IÁ, Dorca J, Martínez S, López NB, Fernández SD, Cuyàs E, Visa J, Rodríguez-Gallego E, Quirantes-Piné R, Segura-Carretero A, Joven J, Martin-Castillo B, Menendez JA. “Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin”. Oncotarget. 2013;4:1484-95. PMID: 23986086. I.F.: 6,63. 6. Corominas-Faja B, Cufí S, Oliveras-Ferraros C, Cuyàs E, López-Bonet E, Lupu R, Alarcón T, Vellon L, Iglesias JM, Leis O, Martín ÁG, Vazquez-Martin A, Menendez JA. “Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway”. Cell Cycle. 2013;12:3109-24. PMID: 23974095. I.F.: 5,01. 7. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, CorominasFaja B, Cuyàs E, López-Bonet E, Martin-Castillo B, Joven J, Menendez JA. “The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in
88
8. Cufí S, Bonavia R, Vázquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, Martin-Castillo B, BarrajónCatalán E, Visa J, Segura-Carretero A, Joven J, Bosch-Barrera J, Micol V, Menendez JA. “Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo”. Scientific Reports. 2013;3:2459. PMID: 23963283. I.F.: 5,08. 9. Cufí S, Bonavia R, Vázquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, BarrajónCatalán E, Visa J, Segura-Carretero A, Bosch-Barrera J, Joven J, Micol V, Menendez JA. “Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells”. Food and Chemical Toxicology. 2013;60:360-8. PMID: 23916468. I.F.: 2,61. 10. Fernández-Sender L, Alonso-Villaverde C, Rull A, RodríguezGallego E, Riera-Borrull M, Hernández-Aguilera A, Camps J, Beltrán-Debón R, Aragonès G, Menendez JA, Joven J. “A possible role for CCR5 in the progression of atherosclerosis in HIVinfected patients: a cross-sectional study”. AIDS Research and Therapy. 2013;10:11. PMID: 23659629. I.F.: 1,84. 11. Alonso-Villaverde C, Menéndez JA, Joven J. “Metabolic stress in infected cells may represent a therapeutic target for human immunodeficiency virus infection”. Medical Hypotheses. 2013;81:125-30. PMID: 23639282. I.F.: 1,15. 12. Vázquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cufí S, Dalla Venezia N, Menendez JA. “Serine79phosphorylated acetyl-CoA carboxylase, a downstream target of AMPK, localizes to the mitotic spindle poles and the cytokinesis furrow”. Cell Cycle. 2013;12:1639-41. PMID: 23603990. I.F.: 5,01. 13. Menéndez JA, Joven J, Cufí S, Corominas-Faja B, OliverasFerraros C, Cuyàs E, Martin-Castillo B, López-Bonet E, Alarcón T, Vazquez-Martin A. “The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells”. Cell Cycle. 2013;12:1166-79. PMID: 23549172. I.F.: 5,01. 14. Alonso-Ruano M, López-Bonet E, Huerta-Anaya MV, VilaCamps E, Bernadó L, Tuca-Rodríguez F, Suarez-Pumariega P, Menendez JA. “Synchronous solid neuroendocrine breast carcinoma and abdominal lymphoma: A case report and review of the literature”. Oncology Letters. 2013;5:459-462. PMID: 23419985. I.F.:0,99.
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ONCOLOGY AND HEMATOLOGY AREA
15. Menéndez JA, Joven J, Aragonès G, Barrajón-Catalán E, Beltrán-Debón R, Borrás-Linares I, Camps J, Corominas-Faja B, Cufí S, Fernández-Arroyo S, Garcia-Heredia A, HernándezAguilera A, Herranz-López M, Jiménez-Sánchez C, LópezBonet E, Lozano-Sánchez J, Luciano-Mateo F, Martin-Castillo B, Martin-Paredero V, Pérez-Sánchez A, Oliveras-Ferraros C, Riera-Borrull M, Rodríguez-Gallego E, Quirantes-Piné R, Rull A, Tomás-Menor L, Vazquez-Martin A, Alonso-Villaverde C, Micol V, Segura-Carretero A. “Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents”. Cell Cycle. 2013;12:555-78. PMID: 23370395. I.F.: 5,01. 16. Vázquez-Martin A, Corominas-Faja B, Cufi S, Vellon L, Oliveras-Ferraros C, Menendez OJ, Joven J, Lupu R, Menendez JA. “The mitochondrial H(+)-ATP synthase and the lipogenic switch: new core components of metabolic reprogramming in induced pluripotent stem (iPS) cells”. Cell Cycle. 2013;12:207-18. PMID: 23287468. I.F.: 5,01. 17. Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Moreno JM, Corominas-Faja B, Urruticoechea A, Martín ÁG, López-Bonet E, Menendez JA. “Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)”. Cell Cycle. 2013;12:225-45. PMID: 23255137. I.F.: 5,01. 18. Rodríguez-Gallego E, Riera-Borrull M, Hernández-Aguilera A, Mariné-Casadó R, Rull A, Beltrán-Debón R, Luciano-Mateo F, Menendez JA, Vazquez-Martin A, Sirvent JJ, Martín-Paredero V, Corbí AL, Sierra-Filardi E, Aragonès G, García-Heredia A, Camps J, Alonso-Villaverde C, Joven J. “Ubiquitous transgenic overexpression of C-C chemokine ligand 2: a model to assess the combined effect of high energy intake and continuous low-grade inflammation”. Mediators of Inflammation. 2013;2013:953841. PMID: 24453432. I.F.: 2,42. 19. Roldán C, de la Torre A, Mota S, Morales-Soto A, Menéndez J, Segura Carretero A. “Identification of active compounds in vegetal extracts based on correlation between activity and HPLC-MS data”. Food Chemistry. 2013;136:392-9. PMID: 23122076. I.F.: 3,26. Reviews (I.F.: 16,15): 1. Hernández-Aguilera A, Rull A, Rodríguez-Gallego E, Riera-Borrull M, Luciano-Mateo F, Camps J, Menéndez JA, Joven J. “Mitochondrial dysfunction: a basic mechanism in inflammation-related non-communicable diseases and therapeutic opportunities”. Mediators of Inflammation. 2013;2013:135698. PMID: 23533299. I.F.: 2,42.
Wang C, Wolvetang E, Vazquez-Martin A, Zhang J. “Autophagy in stem cells”. Autophagy. 2013;9:830-49. PMID: 23486312. I.F.: 11,42. 3. Joven J, Rull A, Rodriguez-Gallego E, Camps J, Riera-Borrull M, Hernández-Aguilera A, Martin-Paredero V, SeguraCarretero A, Micol V, Alonso-Villaverde C, Menéndez JA. “Multifunctional targets of dietary polyphenols in disease: a case for the chemokine network and energy metabolism”. Food and Chemical Toxicology. 2013;51:267-79. PMID: 23063595. I.F.: 2,61.
Grants for research in progress: - Contratos Postdoctorales de Perfeccionamiento en Investigación en Salud “Sara Borrell” (CD08/00283) Sponsored by: Instituto de Salud Carlos III Duration: 2009 - 2012 Javier A. Menéndez - Ensayo en fase II, aleatorizado, abierto, multicéntrico de tratamiento neoadyuvante con quimioterapia y trastuzumab con o sin la adición de metformina en mujeres diagnosticadas de cáncer de mama primario HER2/ErbB2 positivo. (EC10-125) Sponsored by: Ministerio de Sanidad. Duration: 2010 - 2013 Begoña Martin Castillo (Javier A. Menéndez, Investigador Colaborador-Coordinador Científico del Proyecto) - Metabolismo bioenergético y autofagia en las celulas madre tumorales: bases moleculares para la definición de subtipos metabolo-genómicos intrínsecos del cáncer de mama. (SAF2012-38914) Sponsored by: Ministerio de Economía y Competitividad Duration: 2013 - 2015 Javier A. Menéndez - Análisis del papel de las proteínas ID (Inhibitor of Differentiation) en el mecanismo de resistencia a erlotinib mediante la transición epitelio-mesénquima (EMT) en cáncer de pulmón con mutación activadora del EGFR (Epidermal Growth Factor Receptor) Sponsored by: Spanish Society of Medical Oncology (SEOM) Duration: 2013 - 2014 Joaquim Bosch y Javier A. Menéndez - Formación de personal investigador FPI-MICINN 2010 (BES2010-032066) Sponsored by: MICINN Javier A. Menéndez Beneficiary: Sílvia Cufí
2. Guan JL, Simon AK, Prescott M, Menendez JA, Liu F, Wang F,
89
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi ICS INTERNAL MEDICINE MICROBIOLOGY AND INFECTIONS IN THE CRITICAL PACIENT NEPHROLOGY UNIVERSITY OF GIRONA BIOCHEMISTRY OF CANCER BIOPHARMACEUTICAL RESEARCH COMPUTER VISION AND ROBOTICS CONTROL ENGINEERING AND INTELLIGENT SYSTEMS HEALTH AND HEALTHCARE HEALTH PSYCHOLOGY PROTEIN ENGINEERING STATISTICS AND DATA ANALYSIS STATISTICS, ECONOMETRICS AND HEALTH (GRECS)
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
91
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
ICS INTERNAL MEDICINE Group members Group Leader: Ferran García-Bragado
Publications
Molino F, Valle R, Barrón M, Maestre A, Monreal M; RIETE investigators. “Platelet count and outcome in patients with acute venous thromboembolism”. Thrombosis and Haemostasis. 2013;110:1025-34. PMID: 23925476. I.F.: 5.76.
Multicentric (I.F.: 198.84): Uresandi F, Monreal M, García-Bragado F, Domenech P, Lecumberri R, Escribano P, Zamorano JL, Jiménez S, Ruiz-Artacho P, Lozano F, Romera A, Jiménez D; National Consensus on Diagnosis, Risk Stratification and Treatment of Patients With Pulmonary Thromboembolism, Bellmunt S, Cuenca J, Fernández Á, Fernández F, Ibáñez V, Lozano F, March JR, Romera A, Almenar L, Castro A, Escribano P, Lázaro M, Luis Zamorano J, Alonso JR, Ramón Casal J, Miguel Franco J, Jiménez S, Merlo M, Perales R, Piñera P, RuizArtacho P, Suero C, Barba R, Fernández-Capitán C, GarcíaBragado F, Gómez V, Monreal M, Nieto JA, Riera-Mestre A, Suárez C, Trujillo-Santos J, Conget F, Jara L, Jiménez D, Lobo JL, de Miguel J, Nauffal D, Oribe M, Otero R, Uresandi F, Domenech P, González-Porras JR, Lecumberri R, Llamas P, Mingot E, Pina E, Rodríguez-Martorell J; : Spanish Society of Pneumology and Thoracic Surgery (SEPAR); Society Española Internal Medicine (SEMI); Spanish Society of Thrombosis and Haemostasis (SETH); Spanish Society of Cardiology (ESC); Spanish Society of Medicine Accident and Emergency (SEMES); Spanish Society of Angiology and Surgery Vascular (SEACV). “National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism. Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Society Española Internal Medicine (SEMI). Spanish Society of Thrombosis and Haemostasis (SETH). Spanish Society of Cardiology (ESC). Spanish Society of Medicine Accident and Emergency (SEMES). Spanish Society of Angiology and Surgery Vascular (SEACV)”. Archivos de Bronconeumologia. 2013;49:534-47. PMID: 24041726. I.F.: 1.82. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism”. New England Journal of Medicine. 2013;369:1406-15. PMID: 23991658. I.F.: 54.42.
Bertoletti L, Quenet S, Laporte S, Sahuquillo JC, Conget F, Pedrajas JM, Martin M, Casado I, Riera-Mestre A, Monreal M; RIETE Investigators. “Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry”. Respiratory Research. 2013;14:75. PMID: 23865769. I.F.: 3.38. Nieto JA, Solano R, Trapero Iglesias N, Ruiz-Giménez N, Fernández-Capitán C, Valero B, Tiberio G, Bura-Riviere A, Monreal M; RIETE Investigators. “Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism”. Thrombosis Research. 2013;132:175-9. PMID: 23849097. I.F.: 2.43. Lecumberri R, Alfonso A, Jiménez D, Fernández Capitán C, Prandoni P, Wells PS, Vidal G, Barillari G, Monreal M; RIETE investigators. “Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism”. Thrombosis and Haemostasis. 201;110:834-43. PMID: 23846721. I.F.: 5.76. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. “Oral apixaban for the treatment of acute venous thromboembolism”. New England Journal of Medicine. 2013;369:799-808. PMID: 23808982. I.F.: 54.42. Trujillo-Santos J, Schellong S, Falga C, Zorrilla V, Gallego P, Barrón M, Monreal M; RIETE Investigators. “Lowmolecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function”. American Journal of Medicine. 2013;126:425-434.e1. PMID: 23499331. I.F.: 5.30. Otero R, Elías T, Jara L, Trujillo-Santos J, Bertoletti L, Nauffal D, Ruiz-Ruiz J, Blanco-Molina Á, Monreal M; RIETE investigators. “Factors associated with elevated pulmonary
Di Micco P, Ruiz-Giménez N, Nieto JA, Aujesky D, del
92
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
arterial pressure levels on the echocardiographic assessment in patients with prior pulmonary embolism”. Thrombosis Research. 2013;131:e191-5. PMID: 23466216. I.F.: 2.43. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; PLIFY-EXT Investigators. “Apixaban for extended treatment of venous thromboembolism”. New England Journal of Medicine. 2013;368:699-708. PMID: 23216615. I.F.: 54.42. den Exter PL, Gómez V, Jiménez D, Trujillo-Santos J, Muriel A, Huisman MV, Monreal M; Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) Investigators. “A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer”. Chest. 2013;143:138-45. PMID: 22814859. I.F.: 7.13. Gabriel F, Portolés O, Labiós M, Rodríguez C, Cisneros E, Vela J, Nuñez M; RIETE Investigators. “Usefulness of thrombophilia testing in venous thromboembolic disease: findings from the RIETE registry”. Clinical and Applied Thrombosis-Hemostasis. 2013;19:42-7. PMID: 22327823. I.F.: 7.13. Original (I.F.: 2.63): García-Bragado Dalmau F; Grupo de Enfermedad Tromboembólica de la SEMI. “Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism”. Revista Clinica Española. 2013;213:256-7. PMID: 23940850. I.F.: 1.31. Sánchez Fuentes D, Suárez Fernández C, García-Bragado Dalmau F, Mostaza Prieto JM, Conthe Gutiérrez P, Cuende JI. “What was new about vascular risk in the year 2012?” Revista Clinica Española. 2013;213:442-52. PMID: 23932871. I.F.: 1.31.
93
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
Microbiology and infections in the critical pacient Group members Group Leader: Josep Maria Sirvent
Collaborators
Nursing staff
— Anna Baró — Carolina Lorencio — Cristina Murcia — Patricia Ortiz — Abdó Taché
— Aaron Castanera — Guadalupe García — Ana Lobo
Strategic objectives
Main lines of research
More than 10 years ago a research group was created in the IdIBGi called “Microbiology and inflammation”. This group included all projects on infections of the University Hospital of Girona Doctor Josep Trueta (HUGDJT) as well as a group from the University of Girona working in conjunction with them. The leaders of this group were Dr. Josep Maria Sirvent (HUGDJT) and Prof. Jesús García-Gil (UdG).
- Studies of Microbiology and Infections in the critically ill patient. - Study of sepsis. - Study of community-acquired pneumonia.
Over the last three years collaborative research has not been very frequent and, in fact, there is only scientific production in one group and always in reference to infectious diseases in the critically ill patient. It should also be mentioned that Dr. Josep Maria Sirvent forms part of a CIBER respiratory Group, Group 14-Dr. Antoni Torres of Hospital Clínic.
Multicentrics (I.F.: 22.35):
Publications
http://www.ciberes.org/index.php?option=com_ personal&view=personal&grupo_id=14&Itemid=77
Garnacho-Montero J, Gutiérrez-Pizarraya A, Màrquez JA, Zaragoza R, Granada R, Ruiz-Santana S, Rello J, Rodríguez A; Spanish Society of Intensive Care Medicine and Coronary Units Working Group. “Epidemiology, clinical features, and prognosis of elderly adults with severe forms of influenza A (H1N1)”. Journal of the American Geriatrics Society. 2013;61:350-6. PMID: 23496351. I.F.: 4.22.
In order to update the group and suitably redefine the projects and research staff actively involved, we will create an internal specific, dynamic group for the study of infectious diseases in the critically ill patient: Group for Studies of Microbiology and Infections in Critically ill Patients (GMICICU).
Palomar M, Álvarez-Lerma F, Riera A, Díaz MT, Torres F, Agra Y, Larizgoitia I, Goeschel CA, Pronovost PJ; Bacteremia Zero Working Group. “Impact of a national multimodal intervention to prevent catheter-related bloodstream infection in the ICU: the Spanish experience”. Critical Care Medicine. 2013;41:236472. PMID: 23939352. I.F.: 6.15. Esteban A, Frutos-Vivar F, Muriel A, Ferguson ND, Peñuelas O, Abraira V, Raymondos K, Rios F, Nin N, Apezteguía C, Violi DA, Thille AW, Brochard L, González M, Villagomez AJ, Hurtado
94
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
J, Davies AR, Du B, Maggiore SM, Pelosi P, Soto L, Tomicic V, D'Empaire G, Matamis D, Abroug F, Moreno RP, Soares MA, Arabi Y, Sandi F, Jibaja M, Amin P, Koh Y, Kuiper MA, Bülow HH, Zeggwagh AA, Anzueto A. “Evolution of mortality over time in patients receiving mechanical ventilation”. American Journal of Respiratory and Critical Care Medicine. 2013;188: 220-30. PMID: 23631814. I.F.: 11.99. Originals (I.F.: 26.51): Álvarez Lerma F, Carrasco M, Otal JJ, Palomar M, Olaechea P, Peris X, Iglesias L, Martínez Pellus A, Arenzana A, Ballesteros JC; Grupo de Estudio ENVIN-HELICS. “Invasive device-related infections after heart surgery”. Medicina Intensiva. 2013;37:584-92. PMID: 23473741. I.F.: 1.24. Sirvent JM, Carmen de la Torre M, Lorencio C, Taché A, Ferri C, Garcia-Gil J, Torres A. “Predictive factors of mortality in severe community-acquired pneumonia: a model with data on the first 24h of ICU admission”. Medicina Intensiva. 2013;37:308-15. PMID: 23669439. I.F.: 1.24. Martín-Loeches I, Bermejo-Martin JF, Vallés J, Granada R, Vidaur L, Vergara-Serrano JC, Martín M, Figueira JC, Sirvent JM, Blanquer J, Suarez D, Artigas A, Torres A, Diaz E, Rodriguez A; SEMICYUC/REIPI/CIBERES H1N1 Working Group. “Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia”. Intensive Care Medicine. 2013;39:693-702. PMID: 23344833. I.F.: 6.15.
Masclans JR, Pérez M, Almirall J, Lorente L, Marqués A, Socias L, Vidaur L, Rello J; H1N1 GTEI/SEMICYUC Investigators. “Early non-invasive ventilation treatment for severe influenza pneumonia”. Clinical Microbiology and Infection. 2013;19:24956. PMID: 22404211. I.F.: 5.20. Leal Y, Gonzalez-Abril L, Lorencio C, Bondia J, Vehi J. “Detection of correct and incorrect measurements in realtime continuous glucose monitoring systems by applying a postprocessing support vector machine”. IEEE Transactions on Biomedical Engineering. 2013;60:1891-9. PMID: 23380841. I.F.: 2.23. Y. Leal, M. Ruiz, C. Lorencio, J. Bondia, L. Mújica, J. Vehi. “Principal component analysis in combination with case-base reasoning for detecting therapeutically correct and incorrect measurements in continuous glucose monitoring”. Biomedical Signal Processing and Control. 2013; 8: 603-614. I.F.: 1.53. Merino P, Martín MC, Alonso A, Gutiérrez I, Alvarez J, Becerril F; coordinadores del estudio SYREC. “Medication errors in Spanish intensive care units”. Medicina Intensiva. 2013;37:3919. PMID: 23312908. I.F.: 1.24.
Rello J, Gattarello S, Souto J, Sole-Violan J, Valles J, Peredo R, Zaragoza R, Vidaur L, Parra A, Roig J; CommunityAcquired Pneumonia in Unidad de Cuidados Intensivos 2 CAPUCI 2 Study Investigators. “Community-acquired Legionella Pneumonia in the intensive care unit: Impact on survival of combined antibiotic therapy”. Medicina Intensiva. 2013;37:320-6. PMID: 22854618. I.F.: 1.24. Alvarez-Lerma F, Gracia-Arnillas MP, Palomar M, Olaechea P, Insausti J, López-Pueyo MJ, Otal JJ, Gimeno R, Seijas I; Grupo de Investigadores del Estudio Nacional de Vigilancia de Infección Nosocomial en UCI. “Urethral catheter-related urinary infection in critical patients admitted to the ICU. Descriptive data of the ENVIN-UCI study”. Medicina Intensiva. 2013;37:75-82. PMID: 22579562. I.F.: 1.24. Rello J, Afonso E, Lisboa T, Ricart M, Balsera B, Rovira A, Valles J, Diaz E; FADO Project Investigators. “A care bundle approach for prevention of ventilator-associated pneumonia”. Clinical Microbiology and Infection. 2013;19:3639. PMID: 22439889. I.F.: 5.20.
95
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
NEPHROLOGY Group members Group Leader: Ferran García-Bragado
Post-graduate researchers — Jordi Calabia — Isabel García — Nàdia Martin
Collaborators
Nursing staff
— Yaima Barreiro — Christian Cordoba — Maria Cufí — Cristina Martinez — Gerard Maté — Carolina Molina — Cristina Noboa — Pere Torguet
— Jennifer Moreno — Montse Jubany
Strategic objectives
Main lines of research
Consolidate the method for studying cardiovascular risk and the atheroma burden in patients with chronic kidney disease, high blood pressure and Diabetes Mellitus with diabetic nephropathy.
Study of the macro and microvascular affectation of inflammatory markers and bone-mineral metabolism markers in chronic kidney disease and their most frequent pathologies: high blood pressure and diabetic nephropathy.
96
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
Publications Case Report (I.F.: 8.52): Faur D, Pérez-Bovet J, Ferrer SM, Prats MV. “Pathologic cervical fracture in a patient with secondary hyperparathyroidism”. Kidney International. 2013; 83:974. PMID: 23633065. I.F.: 8.52. Multicentrics (I.F.: 61.59): de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, ChristSchmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators. “Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease”. New England Journal of Medicine. 2013;369:2492-503. PMID: 24206459. I.F.: 54.42. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A; ESHOL Study Group. “High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients”. Journal of the American Society of Nephrology. 2013;24:487-97. PMID: 23411788. I.F.: 9.47. González MT, Ramos R, Vera M, Barbosa F, Garcia C, Garcia I, González-Segura C, Cuxart M, Teixidó J, José de la Cruz J. “Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients”. Renal Failure. 2013;35:314-9. PMID: 23356501. I.F.: 0.78. Original (I.F.: 2.55): B.Guasch, P.Torguet, I.García, J.Calabia, N.Martín, G.Maté, D.Faur,Y.Barreiro, C.P. Molina, C.Noboa y M.Vallès. “Utilidad de la monitorización ambulatoria de la presión arterial en la evaluación de la rigidez arterial. Correlaciones con la velocidad de onda del pulso y las tensiones arteriales centrales”. Hipertensión y Riesgo Vascular. 2013; 30: 4-11. Isabel García, Diana Faur, Ramón Farrès, Antoni Codina. “Laparoscopia como técnica eficaz para la colocación del catéter peritoneal”. Nefrología 2013; 33: 137-8. PMID: 2336464. I.F.: 1.44. Faur D, Torguet-Escuder P, Vallès-Prats M. “Severe dysfunction of pacemaker due to hyperkalaemia”. Nefrología. 2013;33:612-3. PMID: 23897202. I.F.: 1.44.
97
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
University of Girona BIOCHEMISTRY OF CANCER Group members Group Leader: Rafael de Llorens and Rosa Peracaula
Senior researchers
Post-doctorate researchers
Post-graduate researchers
— Rosa Núria Aleixandre — Josep Comet — Mª José Ferri — Mª Angeles Martínez — Manuel Ramirez
— Sílvia Barrabés — Esther Llop — Anna Massaguer
— Mertixell Balmaña — Montserrat Ferrer — Marta González — Eva Plà
Publications Originals (I.F.: 10.41): Panosa C, Tebar F, Ferrer-Batallé M, Fonge H, Seno M, Reilly RM, Massaguer A, De Llorens R. “Development of an epidermal growth factor derivative with EGFR blocking activity”. PLoS One. 2013;8:e69325. PMID: 23935985. I.F.: 3.53 Sekhar SC, Kasai T, Satoh A, Shigehiro T, Mizutani A, Murakami H, El-Aarag BY, Salomon DS, Massaguer A, de Llorens R, Seno M. “Identification of caveolin-1 as a potential causative factor in the generation of trastuzumab resistance in breast cancer cells”. Journal of Cancer. 2013;4:391-401. PMID: 23833684. I.F.: 2.64 Pérez-Garay M, Arteta B, Llop E, Cobler L, Pagès L, Ortiz R, Ferri MJ, de Bolós C, Figueras J, de Llorens R, VidalVanaclocha F, Peracaula R. “α2,3-Sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues”. International Journal of Biochemistry & Cell Biology. 2013;45:1748-57. PMID: 23726834. I.F.: 4.24
98
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
BIOPHARMACEUTICAL RESEARCH Group members Group Leader: Maria Teresa Puig
Post-doctorate researchers
Post-graduate researchers
— Glòria Oliveras — Rut Porta
— Zeus Aranda — Adriana Blancafort — Ariadna Giró — Sònia Palomeras — Ferran Pérez — Marc Rabionet — Gemma Viñas
Publications
Grants for research in progress:
Originals (I.F.: 1.25): Xifró X, Puig T, Boadas-Vaello P. “Diagnosis and pharmacological treatment of neuropathic pain in spinal cord injury subjects: from laboratory to clinical trial”. Medicina Clinica. 2013;140:175-81. PMID: 23177311. I.F.: 1.25.
- Estudio de la expresión génica asociado al dolor neuropático: modulación farmacológica Sponsored by: Recercaixa(Fundación Obra Social La Caixa y Asociación Catalana de Universidades Públicas) Duration: 2011-2013 Co-IP: Teresa Puig
Patents: - Authors: Puig T and Blancafort A Title: Trastuzumab and LapatinibResistant cell lines as an screening method for testing the drug antitumor activity in this setting Assignee: Girona University Patente number: P201231228 Priority date: 30/07/2012
- Pre-clinical characterization of fatty acid synthase (FASN) inhibition in anti-HER2 drugresistant models Sponsored by: Instituto de Salud Carlos III. FIS (PI11/00692) Duration: 2012 - 2014 Teresa Puig - Determination of the cellular and molecular interactions of mTOR inhibitors (Temsirolimus) with FASNHER2 metabolic pathway inhibitors (II) Sponsored by: Pfizer (WS10669423) Duration: 2011- 2013 Teresa Puig
99
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
COMPUTER VISION AND ROBOTICS Recognised as a consolidated research group (2009 SGR 380)
Group members Group Leader: Joan Martí
Post-doctorate researchers
Post-graduate researchers
— Yago Díez — Jordi Freixenet — Rafael García — Xavier Lladó — Robert Martí — Arnau Oliver
— Mariano Cabezas — Sonia Durand — Onur Ganiler — Eloy Garcia — Soumya Ghose — Albert Gubern — Konstantin Korotkov — Guillaume Lemaître
Publications
— Joan Massich — Jhimli Mitra — Gerard Pons — Josep Quintana — Mojdeh Rastgodastjerdi — Eloy Roura — Meritxell Tortajada — Sergi Valverde
Grants for research in progress:
Originals (I.F.: 5.21): Ghose S, Oliver A, Mitra J, Martí R, Lladó X, Freixenet J, Sidibé D, Vilanova JC, Comet J, Meriaudeau F. “A supervised learning framework of statistical shape and probability priors for automatic prostate segmentation in ultrasound images”. Medical Image Analysis. 2013;17:587-600. PMID: 23666263. I.F: 3.68. Pons G, Martí J, Martí R, Ganau S, Vilanova JC, Noble J.A. “Evaluating Lesion Segmentation on Breast Sonography as Related to Lesion type” Journal of Ultrasound in Medicine, 2013; 32; 1659-1670. PMID: 23980229. I.F: 1.53
- ASSURE: Personalised Breast Cancer Screening Sponsored by: European Comission – 7th Framework Program Duration: 2012-2015 Robert Martí - AVALEM: Avaluació de l’Atròfia en pacients amb lesions d’Esclerosi Múltiple Sponsored by: CEMCAT, BECA CEM Duration: 2011 – 2013 Xavier Lladó - M3CAD: Multi-modality and multi-view mammographic computer adided diagnosis system Sponsored by: Ministerio de Ciencia e Innovación Duration: 2012-2013 Robert Martí - IA- BIOBREAST: Análisis temporal y detección automática de lesiones en imágenes multimodales – IA- BIOBREASTS Sponsored by: Ministerio de Economia y Competitividad Duration: 2013-2015 Joan Martí
100
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
CONTROL ENGINEERING AND INTELLIGENT SYSTEMS Group members Group Leader: Josep Vehí
Post-doctorate researchers
Post-graduate researchers
— Joaquim Armengol — Remei Calm — Francisco Llaneras — Ningsu Luo Ren
— Inés Ferrer — Maira García — Yenny Teresa Leal — Fabián León — Yeimy Morales — Guangqi Xu
Publications
Grants for research in progress:
Originals (I.F.: 7.53)
- Monitoring & Managing your Health and Well-being Sponsored by: Ministerio de Economía y Competitividad Duration: 2011 - 2014 Josep Vehí
Barcelo-Rico F, Diez JL, Rossetti P, Vehi J, Bondia J. “Adaptive calibration algorithm for plasma glucose estimation in continuous glucose monitoring”. IEEE Journal of Biomedical and Health Informatics. 2013;17:530-8. PMID: 24592455. I.F.: - Leal Y, Gonzalez-Abril L, Lorencio C, Bondia J, Vehi J. “Detection of correct and incorrect measurements in real-time continuous glucose monitoring systems by applying a postprocessing support vector machine”. IEEE Transactions on Biomedical Engineering. 2013;60:1891-9. PMID: 23380841. I.F.: 2.23. Y. Leal, M. Ruiz, C. Lorencio, J. Bondia, L. Mújica, J. Vehi. “Principal component analysis in combination with case-base reasoning for detecting therapeutically correct and incorrect measurements in continuous glucose monitoring”. Biomedical Signal Processing and Control. 2013; 8: 603-614. I.F.: 1.53. Leon-Vargas, Fabian; Garelli, Fabricio; De Battista, Hernan; Vehi, J. “Postprandial blood glucose control using a hybrid adaptive PD controller with insulin-on-board limitation” Biomedical Signal Processing and Control. 2013;8:724-732. I.F.: 1.53
- New strategies for post-prandial glycaemic control using insulin pump therapy in type 1 diabetes (CLOSEDLOOP4MEAL) Sponsored by: Ministerio de Ciencia e Innovación Duration: 2011 – 2013 Josep Vehí - Advanced Structural Control Strategies for Mitigating the Dynamic Load Effects on Floating Offshore Wind Turbines (WINFLOAT) Sponsored by: Ministerio de Ciencia e Innovación Duration: 2012 - 2014 N. Luo
Revert, A.; Garelli, F.; Pico, J.; Vehi, J “Safety Auxiliary Feedback Element for the Artificial Pancreas in Type 1 Diabetes”. IEEE Transactions on Biomedical Engineering. 2013;60:2113-2122. PMID: 23380841. I.F.: 2.23.
101
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
HEALTH AND HEALTHCARE Group members Group Leader: Dolors Juvinyà
Post-doctorate researchers
Post-graduate researchers
— Carme Bertran — Concepció Fuentes
— David Ballester — Neus Brugada — Josep Olivet
Secretary — Alme Domingo
Publications Originals: Juvinya-Canal D. “Salutogenesis, new perspectives to promote health]. Enferm Clin. 2013;23:87-8. PMID: 23664303.
102
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
HEALTH PSYCHOLOGY Recognised as a consolidated research group by the Generalitat of Catalonia: 2009 SGR 618
Group members Group Leader: Mª Eugènia Gras and Montserrat Planes
Post-doctorate researchers
Post-graduate researchers
— Maria Aymerich — Natàlia Cebrián — Mònica Cunill — Sílvia Font-Mayolas — Armand Grau — Josefina Patiño — Rosa Suñer — Maria Carme Timoneda
— Anna Belén Gómez — Francesc Prat
Main lines of research
Publications
The research lines of the group are included in the field of health psychology. The perspective is, therefore, biopsychosocial. The priority lines of research are:
Originals (I.F.:2.44): Font-Mayolas S, Gras ME, Cebrián N, Salamó A, Planes M, Sullman MJ. “Types of polydrug use among Spanish adolescents”. Addictive Behaviors. 2013;38:1605-9. PMID: 23254205. I.F.: 2.44.
Sexual behaviour of risk and prevention of AIDS, other STD and unwanted pregnancies. Behaviour of risk and prevention for users of motor vehicles and pedestrians. Substance dependence. Stress, pain and quality of life. Quality of life during aging. Processes of loss and mourning. Research in education in Health Psychology.
103
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
PROTEIN ENGINEERING Group members Group Leader: Maria Vilanova
Senior researchers — Antoni Benito — Marc Ribó
Post-doctorate researchers
Post-graduate researchers
— Jessica Castro
— Mariona Callís — Glòria García — Veronica Gordo — Santiago Ruiz — David Soler — Anna Vert
Publications
Grants for research in progress:
Originals (I.F.: 8.07):
- Grup d’investigació consolidat (SGR2009-657) Sponsored by: DGU Generalitat de Cataluña Duration: 2009 - 2013 Maria Vilanova
Callís M, Serrano S, Benito A, Laurents DV, Vilanova M, Bruix M, Ribó M. “Towards tricking a pathogen’s protease into fighting infection: the 3D structure of a stable circularly permuted onconase variant cleavedby HIV-1 protease”. PLoS One. 2013;8:e54568. PMID: 23349931. I.F.: 3.53. Serrano S, Callís M, Vilanova M, Benito A, Laurents DV, Ribó M, Bruix M. “(1)H, (13)C and (15)N resonance assignments of the Onconase FL-G zymogen”. Biomolecular NMR Assignments. 2013;7:13-5. PMID: 22392335. I.F.: 0.82. Castro, J. Ribó, M, Benito, A, Vilanova M. “MiniReview: Nucleus-Targeted ribonucleases as antitumor drugs” Current Medicinal Chemistry 2013:1225-31. PMID: 23432583. I.F.: 3.72
104
- Microscopio Láser Espectral Confocal (UNGI10-4E-471) Sponsored by: Ministerio de Ciencia y Innovación. Convocatoria de Infraestructura Científico Tecnológica Duration: 2012 - 2016 Marc Ribó Panosa - Estudis estructurals i funcionals de inteínas i ribonucleases per a l’obtenció de molècules amb aplicacions biotecnològiques i biomèdiques. (SING12/04) Sponsored by: Universitat de Girona Duration: 2012 - 2013 Antoni Benito Mundet
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
STATISTICS AND DATA ANALYSIS Group members Group Leader: Josep Antoni Martín
Post-doctorate researchers
Post-graduate researchers
— Carles Barceló — Josep Daunis — Santiago Thió Fernández — M. Gloria Mateu — Vera Pawlowsky
— Marc Comas — Iván Galván — Marina Vives
Publications Originals (I.F.: 16.37): Puig J, Blasco G, Daunis-I-Estadella J, Thomalla G, Castellanos M, Figueras J, Remollo S, van Eendenburg C, SánchezGonzález J, Serena J, Pedraza S. “Decreased corticospinal tract fractional anisotropy predicts long-term motor outcome after stroke”. Stroke. 2013;44:2016-8. PMID: 23652266. I.F.: 6.02 Puig J, Blasco G, Daunis-I-Estadella J, Thomalla G, Castellanos M, Soria G, Prats-Galino A, Sánchez-González J, Boada I, Serena J, Pedraza S. “Increased corticospinal tract fractional anisotropy can discriminate stroke onset within the first 4.5 hours”. Stroke. 2013;44:1162-5. PMID: 23463753. I.F.: 6.02 Puig J, Blasco G, Essig M, Daunis-I-Estadella J, Laguillo G, Quiles AM, Remollo S, Bergmann K, Joly C, Bernado L, Sánchez-González J, Pedraza S. “Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma”. European Radiology. 2013;23:1093-101. PMID: 23085863. I.F.: 4.34
105
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
STATISTICS, ECONOMETRICS AND HEALTH (GRECS) Group members Group Leader: Marc Sáez
Post-doctorate researchers
Post-graduate researchers
— Maria Antònia Barceló — Germà Coenders — Lluís Coromina — Rafael Marcos-Gragera — Gemma Renart — Carme Saurina
— Elena Arroyo — Basili Bragulat — Carme Cañizares — Berta Ferrer — Laia Maynou — Montserrat Puig — Gemma Osca — Amjad Abu Rmileh — Laura Serra
Publications
malignancies: fifteen years of epidemiological data in the province of Girona, Spain”. Haematologica. 2013;98:e95-7. PMID: 23812933. I.F.: 5.87.
Originals (I.F.: 56.01): Gotsens M, Marí-Dell’Olmo M, Pérez K, Palència L, MartinezBeneito MA, Rodríguez-Sanz M, Burström B, Costa G, Deboosere P, Domínguez-Berjón F, Dzúrová D, Gandarillas A, Hoffmann R, Kovacs K, Marinacci C, Martikainen P, Pikhart H, Rosicova K, Saez M, Santana P, Riegelnig J, Schwierz C, Tarkiainen L, Borrell C. “Socioeconomic inequalities in injury mortality in small areas of 15 European cities”. Health& Place. 2013;24:165-72. PMID: 24112963. I.F.: 2.44. Renart G, Saez M, Saurina C, Marcos-Gragera R, Ocaña-Riola R, Martos C, Barceló MA, Arribas F, Alcalá T. “A common error in the ecological regression of cancer incidence on the deprivation index”. Revista Panamericana de Salud Publica. 2013;34:83-91. PMID: 24096972. I.F.: 0.72. Mata-Cases M, Benito-Badorrey B, Roura-Olmeda P, Franch-Nadal J, Pepió-Vilaubí JM, Saez M, Coll-de-Tuero G; GEDAPS (Primary Care Group for the study of Diabetes) of the Catalonian Society of Family and Community Medicine. “Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care”. Current Medical Research and Opinion. 2013;29:1495-502. PMID: 23944631. I.F.: 2.37. Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Lloveras N, Marcos-Gragera R. “Population-based incidence of myeloid
106
Saurina C, Bragulat B, Saez M, López-Casasnovas G. “A conditional model for estimating the increase in suicides associated with the 2008-2010 economic recession in England”. Journal of Epidemiology and Community Health. 2013;67:779-87. PMID: 23794615. I.F.: 3.29. Delgado-Rodríguez M, Castilla J, Godoy P, Martín V, Soldevila N, Alonso J, Astray J, Baricot M, Galán JC, Castro A, GónzálezCandelas F, Mayoral JM, Quintana JM, Pumarola T, Tamames S, Sáez M, Domínguez A; CIBERESP Cases and Controls in Pandemic Influenza Working Group, Spain. “Different prognosis in hospitalized patients with influenza one season after the pandemic H1N1 influenza of 2009-2010 in Spain”. Influenza and Other Respiratory Viruses. 2013;7:1336-42. PMID: 23647645. I.F.: 1.90 Domínguez A, Castilla J, Godoy P, Delgado-Rodríguez M, Saez M, Soldevila N, Astray J, Mayoral JM, Martín V, Quintana JM, González-Candelas F, Galán JC, Tamames S, Castro A, Baricot M, Garín O, Pumarola T; CIBERESP Cases and Controls in Pandemic Influenza Working Group (Spain). “Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons”. Human Vaccines & Immunotherapeutics.
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
Groups associated with the IdIBGi
2013;9:865-73. PMID: 23563516. I.F.: 2.13 Castilla J, Godoy P, Domínguez A, Martínez-Baz I, Astray J, Martín V, Delgado-Rodríguez M, Baricot M, Soldevila N, Mayoral JM, Quintana JM, Galán JC, Castro A, GonzálezCandelas F, Garín O, Saez M, Tamames S, Pumarola T; CIBERESP Cases and Controls in Influenza Working Group Spain. “Influenza vaccine effectiveness in preventing outpatient, inpatient, and severe cases of laboratoryconfirmed influenza”. Clinical Infectious Diseases. 2013;57:16775. PMID: 23532475. I.F.: 9.42 Domínguez A, Castilla J, Godoy P, Delgado-Rodríguez M, Saez M, Soldevila N, Astray J, María Mayoral J, Martín V, María Quintana J, González-Candelas F, Galán JC, Tamames S, Acosta AC, Baricot M, Garín O, José García J, Moraga F, Pumarola T; CIBERESP Cases and Controls in Pandemic Influenza Working Group Spain. “Benefit of conjugate pneumococcal vaccination in preventing influenza hospitalization in children: a case-control study”. Pediatric Infectious Disease Journal. 2013;32:330-4. PMID: 23337901. I.F.: 1.14 Castilla J, Godoy P, Domínguez Á, Martín V, DelgadoRodríguez M, Martínez-Baz I, Baricot M, Soldevila N, Mayoral JM, Astray J, Quintana JM, Cantón R, Castro A, González-Candelas F, Alonso J, Saez M, Tamames S, Pumarola T; CIBERESP Cases and Controls in Influenza Working Group. “Risk factors and effectiveness of preventive measures against influenza in the community”. Influenza and Other Respiratory Viruses. 2013;7:177-83. PMID: 22458533. I.F.: 1.90 Crocetti E, Caldarella A, Ferretti S, Ardanaz E, Arveux P, Bara S, Barrios E, Bento MJ, Bordoni A, Buzzoni C, Candela G, Colombani F, Delafosse P, Federico M, Francart J, Giacomin A, Grosclaude P, Guizard AV, Izarzugaza I, Konzelmann I, La Rosa F, Lapotre B, Leone N, Ligier K, Mangone L, MarcosGragera R, Martinez R, Michelena MJ, Michiara M, Miranda A, Molinié F, Mugarza-Gomez C, Paci E, Piffer S, Puig-Vives M, Sacchettini C, Sánchez MJ, Traina A, Tretarre B, Tumino R, Van Vaerenbergh E, Velten M, Woronoff AS. “Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries”. Breast. 2013;22:476-81. PMID: 23669022. I.F.: 2.58
Puig-Vives M, Sánchez MJ, Sánchez-Cantalejo J, TorrellaRamos A, Martos C, Ardanaz E, Chirlaque MD, Perucha J, Díaz JM, Mateos A, Machón M, Marcos-Gragera R. “Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study”. Gynecologic Oncology. 2013;130:609-14. PMID: 23747837. I.F.: 3,69 Murillo C, Saurina C. “Medida de la importancia de las dimensiones de la satisfacción en la provisión de servicios de salud”. Gaceta Sanitaria 2013; 22:304-309. PMID: 23416027. I.F.: 1.25 Maynadié M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, Capocaccia R, Giacomin A, Lutz JM, Martos C, Sankila R, Johannesen TB, Simonetti A, Sant M; HAEMACARE Working Group. “Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study”. Haematologica. 2013;98:230-8. PMID: 22983589. I.F.: 5,87 Coromina L, Saris WE. “External validity for one-dimensional cumulative scaling on supranational political decisionmaking”. Journal of Social Research & Policy 2013; 4. Coromina L. “Supranationalism decision making for Spanish citizens and its relation to personal variables”. Social Indicators Research 2013; 110:245-256. I.F.: 1.45 Multicentrics (I.F.: 4.82): van der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, Dei Tos AP, Baudin E, Poston G, Links T; the RARECARE WG. “Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project”. European Journal of Cancer 2013;49:2565-78. PMID: 23541566. I.F.: 4.82 Books Renart G, Serra L, Coenders G, Coromina Ll, Saurina C, Saez M. “Estadística amb R-Commander”. Girona: Documenta Universitaria y Universidad de Girona, UdG Publicacions, Quaderns 13, 2013.
Gatta G, Rossi S, Foschi R, Trama A, Marcos-Gragera R, Pastore G, Peris-Bonet R, Stiller C, Capocaccia R; EUROCARE Working Group. “Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002”. Haematologica. 2013;98:744-52. PMID: 23403323. I.F.: 5.87
107
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ANNEXES Annex 1. Clinical Trials List ALLERGY SERVICES MER-ACA-2013-02. Mª Teresa Cerdà Trias. “Efectividad y adherencia de un extracto alergoide de alta dosis (Acaroid®): Seguimiento durante 2 años de tratamiento” CARDIOLOGY EFC11570. Pablo Loma-Osorio Ricon. “Ensayo aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar el efecto de SAR236553/REGN727 sobre la aparición de acontecimientos cardiovasculares en pacientes que han experimentado recientemente un síndrome coronario agudo” SURGERY CCRe-IV. David Julià Bergkvist. “Ensayo clínico multicéntrico aleatorizado en pacientes con cáncer colo-rectal con metástasis irresecables. Impacto de la resección tumoral vs quimioterapia sola sobre la supervivencia” GASTROINTESTINAL SERVICES ES1780C. Glòria Vaquer. “Estudio Epidemiológico y de afectación psicológica del paciente ostomizado temporal y definitivo” ENDOCRINOLOGY AND METABOLIC MEDICINE CLAF237A2411. Mercè Fernández Balsells. “Estudio multicéntrico, aleatorizado, doble ciego, con doble simulación para evaluar el perfil de tolerabilidad y eficacia de vildagliptina en comparación con gliclazida como terapia dual con metformina en pacientes musulmanes con diabetes tipo 2 en ayuno durante el Ramadán” MK-3102-018. Mercè Fernández Balsells. “Estudio aleatorizado, en doble ciego, controlado con placebo y multicéntrico, para evaluar los resultados cardiovasculares tras el tratamiento con MK-3102 en sujetos con diabetes mellitus de tipo 2)” MID-Frail. Mercè Fernández Balsells. “Ensayo clínico aleatorizado para evaluar la efectividad de un programa de intervención multimodal en pacientes diabéticos tipo 2 prefrágiles y frágiles sobre la fragilidad y la calidad de vida” INTERNAL MEDICINE 11-019. Antoni Castro Guardiola. “Estudio multicéntrico, aleatorizado, con control activo de eficacia y seguridad que compara betrixaban en tratamiento prolongado con Enoxaparina® como tratamiento habitual para la prevención del tromboembolismo venoso en pacientes con enfermedad medicamente aguda”
POD-TAR-2011-01. Delia García Pares. “Medidas de salud autopercibidas por los pacientes infectados por VIH que cambian su TARGA previo a un régimen de un comprimido una vez al día por intolerancia en la práctica clínica habitual” DAI-VTE-2013-01. Ferrán García-Bragado Dalmau. “Prevención de episodios de tromboembolia – Registro europeo sobre tromoembolia venosa. PREFER en VTE” CRITICAL CARE BAY 41-6551/13085. José María Sirvent Calvera. “Estudio prospectivo, aleatorizado, doble ciego, controlado con placebo y multicéntrico, para evaluar la seguridad y la eficacia de BAY 41-6551 como tratamiento adyuvante en pacientes con neumonía por Gram negativos intubados y con ventilación mecánica” NEPHROLOGY M11-352. Martí Vallés Prats. “Ensayo multicéntrico, internacional, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo del efecto de atrasentán sobre los resultados renales de sujetos con diabetes tipo 2 y nefropatía. SONAR: ensayo de nefropatía diabética con atrasentán” B1261007. Martí Vallés Prats. “Estudio de fase II multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos, para evaluar la eficacia y la seguridad de la administración una vez al día de un antagonista del receptor de quimiocinas CCR2/5 (PF-04634817) en adultos con diabetes tipo 2 y nefropatía evidente” BAY 94-8862/16243. Martí Vallés Prats. “Ensayo clínico, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y eficacia de diferentes dosis orales de BAY 94-8862 en pacientes con Diabetes Mellitus tipo 2 y con un diagnóstico clínico de nefropatía diabética” NEUROLOGY P261-402. Albert Molins Albanell. “Estudio abierto de seguridad de USL261 en el tratamiento ambulatorio de sujetos con crisis en racimo” RRO-LAC-2012-01. Albert Molins Albanell. “Efecto de la lacosamida sobre síntomas depresivos de ansiedad en pacientes con epilepsias parciales” CD-IA-MEDI-551-1102. Lluís Ramió i Torrentà. “Estudio de fase 1, aleatorizado de MEDI-551 en sujetos con esclerosis múltiple remitente-recidivante” ORAL-CORTEM. Lluís Ramió i Torrentà. “Ensayo clínico, piloto,
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
de no-inferioridad, multicéntrico, con asignación aleatoria y doble ciego, para comparar la eficacia clínica, radiológica de 2 dosis de metilprednisolona administradas por vía oral en pacientes en brote de esclerosis múltiple” LAQ-MS-305 (CONCERTO). Lluís Ramió i Torrentà. “Estudio multinacional, multicéntrico, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo, seguido de un periodo de tratamiento activo, para evaluar la eficacia, la seguridad y la tolerabilidad de dos dosis de laquinimod administradas por vía oral (0,6 mg/día o 1,2 mg/día) en sujetos con esclerosis múltiple remitente-recurrente (EMRR)” MER-INT-2013-01. Lluís Ramió i Torrentà. “Estudio observacional, retrospectivo y transversal para evaluar el cumplimiento subóptimo en pacientes con esclerosis múltiple remitente-recurrente que presentan un brote tras un mínimo de 6 meses de tratamiento con IFN beta-1a” MER-INT-2013-02. Lluís Ramió i Torrentà. “Estudio multicéntrico retrospectivo para evaluar el cumplimiento a largo plazo con el tratamiento con IFN beta-1ª mediante el dispositivo RebiSmart® en pacientes con esclerosis múltiple remitente-recurrente” RPC01-201. Lluís Ramió i Torrentá. “Estudio fase 2/3, multicéntrico, aleatorizado, doble ciego, controlado con placebo (parte A) y doble ciego, con doble simulación y con control activo (parte B), de grupos paralelos para evaluar la eficacia y la seguridad de RPC1063 administrado por vía oral a pacientes con esclerosis múltiple recidivante” MT-1303-E04. Lluís Ramió i Torrentà. “Estudio en fase II, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado por placebo, de búsqueda de dosis para evaluar la seguridad y eficacia de 3 dosis orales distintas de MT1303 administradas durante un periodo de 24 semanas a pacientes con esclerosis múltiple remitente-recidivante” MT-1303-E05. Lluís Ramió i Torrentà. “Estudio en fase II, multicéntrico para evaluar la seguridad y eficacia a largo plazo de MT-1303 en pacientes con esclerosis múltiple remitente-recidivante que hayan completado el estudio MT1303-E04” 205MS303. Lluís Ramió i Torrentà. “A Multicenter, OpenLabel, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301” SHI-FAB-2012-01. Joaquín Serena Leal. “Estudio epidemiológico sobre la sintomatología y evolución clínica
109
de la Enfermedad de Fabry para la valoración del estado de salud de mujeres no tratadas” BC28027. Joaquín Serena Leal. “Estudio de fase 3B para evaluar si Aleglitazar puede reducir el riesgo cardiovascular en pacientes con enfermedad cardiovascular estable y alteraciones de la glucosa” CP-01. Joaquim Serena Leal. “Estudio de fase III, aleatorizado, controlado con placebo, en doble ciego, de la lisis de trombos combinada con ultrasonidos y el activador tisular del plasminógeno (Tpa) sistémico para la revascularización emergente (CLOTBUST-ER) en el ictus isquémico agudo” AGAL 19110 / MSC 12711 (Fabry Map). Joaquín Serena Leal. “Estudio transversal sobre la función renal en varones jóvenes con enfermedad de Fabry sin tratamiento previo” 12649 (DIAS4). Joaquín Serena Leal. “A randomised, doubleblind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke” WAKE-UP. Joaquín Serena Leal. “Efficacy and safety of mri-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial” PEDIATRICS MER-SOM-2011-01. Abel López Bermejo. “Easypod Connect: Estudio observacional, multicéntrico, para estudiar la adherencia y respuesta a largo plazo en pacientes pediátricos tratados con Saizen® vía EasyPodTM” SMT-IIR-26/WI177779. Abel López Bermejo. “Identification of circulating microRNAs in short children born small for gestational age: Relationship with pre- and postnatal growth and metabolic parameters” LUNG CARE (PULMONOLOGY) NOV-EPO-2012-01. Sonia Belda Diaz. “Caracterización fenotípica de la población EPOC en España. Clasificación de fenotipos clínicos de la EPOC y evaluación del diagnóstico y el tratamiento en práctica clínica habitual. Estudio FENEPOC.” CIDD001D2401. Mª Teresa Casamitjà Sot. “Estudio multicéntrico aleatorizado de 52 semanas para evaluar el seguimiento de pacientes a distancia utilizando la herramienta EXACT de resultados percibidos por el paciente sobre la reducción de hospitalizaciones derivadas de reagudizaciones en pacientes con Enfermedad Pulmonar Obstructiva Crónica en comparación con los tratados mediante la asistencia habitual”
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ANNEXES
UROLOGY EMPATHY-P. Lluís Cecchini. “Protocolo Europeo multicéntrico para evaluar la heterogeneidad del tumor mediante genes de progresión del ciclo celular en pacientes con cáncer de próstata en estadio T1-3, N0-X, M0-X” ONCOLOGY MO28113. Pilar Barretina Ginesta. “Estudio de fase II, multicéntrico, doble ciego, randomizado, en dos partes, para evaluar la eficacia y la seguridad de pertuzumab en combinación con quimioterapia estándar frente a placebo más quimioterapia estándar, en mujeres con cáncer epitelial de ovario recurrente, resistente a platino, con expresión baja de HER3 en ARNm” GEICO-1205. Pilar Barretina Ginesta. “Ensayo clínico fase II aleatorizado, abierto y multicéntrico, para determinar la toxicidad y eficacia de quimioterapia pre-quirúrgica con o sin Bevacizumab en pacientes con Cáncer de Ovario Avanzado” GEI-QUI-2010-01. Sonia del Barco Berron. “Estudio prospectivo de las características de los pacientes con tumores cerebrales intra-axiales y su manejo terapéutico, en instituciones españolas” PFM-VIN-2012-01. Sonia del Barco Berron. “Carga global de la enfermedad en pacientes con cáncer de mama avanzado tratados con vinorelbina oral frente a vinorelbina intravenosa (i.v.) y sus cuidadores en Europa” CRAD001YIC04. Sonia del Barco Berron. “Estudio multicéntrico, abierto, de acceso expandido, para mujeres postmenopáusicas con cáncer de mama metastásico o localmente avanzado con receptor estrogénico positivo que han progresado tras tratamiento hormonal previo, que investiga el tratamiento de everolimus (RAD001) en combinación con exemestano”
seguidos por mantenimiento con vinorelbina oral como agente único frente a gemcitabina y cisplatino seguidos de mantenimiento con gemcitabina como agente único en primera línea en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con tipo histológico escamoso” MED-DBL-2012-01. Joan Brunet Vidal. “Estudio observacional, retrospectivo y multicéntrico para evaluar el beneficio clínico de la combinación de trastuzumab y lapatinib (TL) en pacientes con cáncer de mama metastásico HER2 positivo y previamente tratados con trastuzumab y/o lapatinib” EGF117268. Joan Brunet Vidal. “Investigación de mecanismos inmunitarios relacionados con la hepatotoxicidad asociada a lapatinib: investigación biológica ex vivo de linfocitos T en relación con acontecimientos adversos hepáticos inducidos por lapatinib utilizando CMSP obtenidas de una selección de pacientes del estudio EGF105485 (TEACH)” CEL-SMD-2012-01. Rosa Coll Jordà. “Estudio observacional post-autorización para evaluar la evolución en la práctica clínica habitual de pacientes recién diagnosticados de síndrome mielodisplásico (SMD) o leucemia mielomonocítica crónica (LMMC), en función del momento de inicio de tratamiento activo. Estudio ERASME” MO28231. Joan Dorca Ribugent. “Estudio multicéntrico, con un solo grupo de tratamiento, de trastuzumab emtansina (TDM1) en pacientes con cáncer de mama localmente avanzado o metastásico, HER2 positivo, que han recibido previamente tratamiento basado en un agente anti-HER2 y quimioterapia” AP24534-12-301. Cristalina Fernández. “Estudio Fase III, aleatorizado, abierto, de Ponatinib frente a Imatinib en pacientes adultos con Leucemia Mieloide Crónica de nuevo diagnóstico en Fase Crónica”
CDX110-04. Sonia del Barco Berron. “An international, randomized, double-blind, controlled study of Rindopepimut/ GM-CSF with adjuvant temozolomide in patients with newly diagnosed, surgically resected, EGFRVIII-Positive glioblastoma”
CAMN107AIC05. Cristalina Fernández. “Estudio Fase III, prospectivo, aleatorizado, abierto, con dos brazos de tratamiento, para evaluar la tasa de remisión libre de tratamiento (RLT)en pacientes con LMC cromosoma Filadelfia positivo, después de dos duraciones distintas de tratamiento de consolidación con nilotinib 300 mg BID”
20101129 (TRINOVA). Miquel Beltran Fabregat. “Estudio multicéntrico de fase 3, aleatorizado, doble ciego y controlado con placebo de AMG 386 con paclitaxel y carboplatino como tratamiento de primera línea para sujetos con cáncer epitelial de ovario, peritoneal primario o de trompas de falopio en estadio III-IV de la figo”
C14012. Santiago Gardella Company. “Ensayo clínico multicéntrico, internacional, de fase III, de dos grupos, aleatrorizado y abierto de alisertib (MLN8237) o la elección del investigador (agente único seleccionado) en pacientes con linfoma de células T periféricas recidivante o resistente al tratamiento”
PM 0259 CA 230 J1. Joaquim Bosch Barrera. “Estudio aleatorizado en fase II de vinorelbina oral y cisplatino
CD-ON-MEDI-551-1088. Santiago Gardella Company. “Estudio en fase II, aleatorizado y abierto, para evaluación de
ANNEXES
MEDI-551 en adultos con linfoma b difuso de cálulas grandes (LBDCG) recidivante o resistente al tratamiento”
con carcinoma de células escamosas de cabeza y cuello estadio III, IVa o IVb locorregionalmente avanzado”
CEL-MIE-2012-02. Yolanda González Montes. “Registro observacional post-autorización para evaluar el impacto clínico del inicio de la terapia antitumoral de rescate en pacientes con mieloma múltiple (MM) en recaída biológica asintomática frente al inicio del tratamiento en el momento de la recaída sintomática”
ROC-BRA-2012-01. Jordi Rubió Casadevall. “Estudio epidemiológico sobre la mutación BRAF V600 en población española diagnosticada de melanoma metastásico” GEIS 26. Jordi Rubió Casadevall. “Registro de sarcomas raros: Herramienta de ayuda para evaluar el número de casos de cada subtipo y su orientación terapéutica por el Grupo Español de Investigación en Sarcomas (GEIS)”
GEM2012MENOS65. Yolanda González Montes. “Estudio fase III nacional, multicéntrico, abierto, aleatorizado, de tratamiento de inducción con bortezomib/lenalidomida/ dexametasona (VRD-GEM), seguido de altas dosis de quimioterapia con melfalán-200 (MEL-200) vs. busulfánmelfalán (BUMEL) y consolidación con VRD-GEM para pacientes con mieloma múltiple sintomático de nuevo diagnóstico menores de 65 años.”
JAN-CPR-2012-01. Nuria Sala. “Estudio observacional prospectivo para describir el manejo de pacientes con cáncer de próstata metastásico resistente a la castración en segunda línea de tratamiento tras docetaxel, en la práctica clínica habitual” (Estudio CAPRO) PUMA-NER-1301. Gemma Vinyes Villarò. “Estudio de Neratinib más Capecitabina frente a Lapatinib más Capecitabina en pacientes con Cáncer de mama mestastásico HER2+ que han recibido previamente dos o más regímenes anti-HER2 para enfermedad mestastásica (NALA)”
MM>65-Recaída1/YGM-MIE-2013-01. Yolanda González Montes. “Estudio observacional en paciente >= 65 años con mieloma múltiple en primera recaída candidatos a tratamiento de rescate” GECP 10/03. Rut Porta Balanyà. “Estudio fase Ib/IIb, aleatorizado y multicéntrico, para evaluar la eficacia y tolerabilidad de la combinación de gefitinib y olaparib (AZD2281) frente a gefitinib solo, en pacientes con cáncer de pulmón no microcítico avanzado que presenta mutaciones del receptor del factor de crecimiento epidérmico (EGFR)”
RADIOLOGY AND IMAGING INTERRSeCT. Josep Puig Alcántara. “Identifying New approaches to optimize Thrombus characterization for predicting Early Recanalization and Reperfusion with iv tPA and other treatments using Serial CT angiography”
TG4010.14. Rut Porta Balanyà. “Estudio de fase IIb/III aleatorizado, doble ciego, controlado con placebo de comparación del tratamiento de primera línea con o sin el producto de inmunoterapia TG4010 en pacientes con cáncer pulmonar no microcítico (CPNM)” EC-FV-07. Rut Porta Balanyà. “Estudio de fase II, abierto, aleatorizado, de EC145 en monoterapia y la combinación de EC145 más docetaxel frente a docetaxel solo en participantes con CPCNP positivo a receptores de folato [FR(++)] en segunda línea” - código del ensayo” TTCC-2010-06. Jordi Rubió Casadevall. “Ensayo de fase II de un regimén secuencial de quimioterapia de induccion con panitumumab y paclitaxel seguida de radioterapia más panitumumab en pacientes con cáncer de cabeza y cuello localmente avanzado que no son candidatos al tratamiento con derivados del platino” 1200.131. Jordi Rubió Casadevall. “LUX– HEAD & NECK 2. Un estudio aleatorizado, doble ciego, controlado con placebo, en fase III para evaluar la eficacia y la seguridad de afatinib (bibw 2992) como terapia adyuvante tras quimioradioterapia en pacientes no sometidos a resección primaria 111
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
ANNEXES
Annex2. Seminars
Title
Title
Investigació amb grans bases de dades de la historia clínica d’Atenció Primària: Plataforma de recerca SIDIAP
Presentació de l’Acció Estratègica en Salut
Speakers
Speakers Dr. Albert Barberà Sra. Núria Chico
Dr. Bonaventura Bolívar Dra. Maria García Dr. Rafel Ramos
Date 17/05/2013
Date 25/04/2013
Title
Title
Reflexión sobre la investigación en salud: retos de futuro
Presentació del BIOBANC IDIBGI Plataforma de suport a la recerca
Speakers
Speakers
Dr. Lisardo Boscá
Dr. Albert Barberà Dra. Aina Rodríguez
Date 13/06/2013
Date 02/07/2013
Title
Title
Sessió en recerca bibliogràfica
I Sessió - Jornada de transferència IDIBGI -Nocions bàsiques sobre com protegir resultats de recerca de l’àmbit sanitari. -Guia de bones pràctiques i qüestions importants a tenir en compte quan es fa recerca biomèdica i en salut pública i comunitària.
Speakers Sra. Esther Sarrià Date 10/07/2013
Speakers Dr. Alejandro Vaquero Date 13/11/2013
112
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
113
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
114
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
115
ANNUAL SCIENTIFIC REPORT IDIBGI 2013
PATRONS
INSTITUCIONS COL·LABORADORES
Institut d’Investigació Biomèdica de Girona Dr. Josep Trueta Edifici Hospital Universitari de Girona Dr. Josep Trueta Avda. de França s/n. 17007 Girona Tel: +34 972 940 282 fundacio@idibgi.org www.idibgi.org